<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">62394</article-id><article-id pub-id-type="doi">10.7554/eLife.62394</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>ACLY ubiquitination by CUL3-KLHL25 induces the reprogramming of fatty acid metabolism to facilitate iTreg differentiation</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-203930"><name><surname>Tian</surname><given-names>Miaomiao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-203931"><name><surname>Hao</surname><given-names>Fengqi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8640-7244</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203932"><name><surname>Jin</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203933"><name><surname>Sun</surname><given-names>Xue</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203934"><name><surname>Jiang</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203935"><name><surname>Wang</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203936"><name><surname>Li</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203937"><name><surname>Chang</surname><given-names>Tianyi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203938"><name><surname>Zou</surname><given-names>Yingying</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203939"><name><surname>Peng</surname><given-names>Pinghui</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203940"><name><surname>Xia</surname><given-names>Chaoyi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203941"><name><surname>Liu</surname><given-names>Jia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203942"><name><surname>Li</surname><given-names>Yuanxi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-203929"><name><surname>Wang</surname><given-names>Ping</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-203928"><name><surname>Feng</surname><given-names>Yunpeng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6912-3338</contrib-id><email>fengyp0108@nenu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-203722"><name><surname>Wei</surname><given-names>Min</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9945-6961</contrib-id><email>weim750@nenu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Key Laboratory of Molecular Epigenetics of the Ministry of Education (MOE), Northeast Normal University</institution><addr-line><named-content content-type="city">Changchun</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution>Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution>Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution>Tongji University Cancer Center, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Takeda</surname><given-names>Kiyoshi</given-names></name><role>Reviewing Editor</role><aff><institution>Osaka University</institution><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution>Institute of Industrial Science, The University of Tokyo</institution><country>Japan</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>07</day><month>09</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e62394</elocation-id><history><date date-type="received" iso-8601-date="2020-08-23"><day>23</day><month>08</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-08-22"><day>22</day><month>08</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Tian et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Tian et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-62394-v1.pdf"/><abstract><p>Inducible regulatory T (iTreg) cells play a central role in immune suppression. As iTreg cells are differentiated from activated T (Th0) cells, cell metabolism undergoes dramatic changes, including a shift from fatty acid synthesis (FAS) to fatty acid oxidation (FAO). Although the reprogramming in fatty acid metabolism is critical, the mechanism regulating this process during iTreg differentiation is still unclear. Here we have revealed that the enzymatic activity of ATP-citrate lyase (ACLY) declined significantly during iTreg differentiation upon transforming growth factor β1 (TGFβ1) stimulation. This reduction was due to CUL3-KLHL25-mediated ACLY ubiquitination and degradation. As a consequence, malonyl-CoA, a metabolic intermediate in FAS that is capable of inhibiting the rate-limiting enzyme in FAO, carnitine palmitoyltransferase 1 (CPT1), was decreased. Therefore, ACLY ubiquitination and degradation facilitate FAO and thereby iTreg differentiation. Together, we suggest TGFβ1-CUL3-KLHL25-ACLY axis as an important means regulating iTreg differentiation and bring insights into the maintenance of immune homeostasis for the prevention of immune diseases.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>TGFβ1</kwd><kwd>ATP-citrate lyase</kwd><kwd>CUL3-KLHL25</kwd><kwd>ubiquitination</kwd><kwd>iTreg</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>E. coli</italic></kwd><kwd>Human</kwd><kwd>Mouse</kwd><kwd>Virus</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>32070896</award-id><principal-award-recipient><name><surname>Wei</surname><given-names>Min</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31870896</award-id><principal-award-recipient><name><surname>Wei</surname><given-names>Min</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012226</institution-id><institution>Fundamental Research Funds for the Central Universities</institution></institution-wrap></funding-source><award-id>2412019FZ028</award-id><principal-award-recipient><name><surname>Feng</surname><given-names>Yunpeng</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Metabolic flux analysis, biochemistry assays, and functional confirmation in mice show that the ubiquitination and degradation of ATP-citrate lyase (ACLY) mediated by CUL3-KLHL25 promotes the switch from fatty acid synthesis to fatty acid oxidation for iTreg differentiation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>As a critical subset of immunosuppressive cells, regulatory T (Treg) cells play a central role in the suppression of aberrant or excessive immune responses and are critical for the maintenance of immune homeostasis (<xref ref-type="bibr" rid="bib15">Dominguez-Villar and Hafler, 2018</xref>). Defects in Treg frequency or function are often associated with distinct autoimmune disorders, such as system lupus erythematosus (SLE), rheumatoid arthritis (RA), and inflammatory bowel disease (IBD) (<xref ref-type="bibr" rid="bib65">Sakaguchi et al., 2008</xref>; <xref ref-type="bibr" rid="bib75">Tao et al., 2017</xref>). Treg cells are composed of thymus-derived natural Treg (nTreg) and peripheral inducible Treg (iTreg) cells, which are originated and matured at different locations in the body (<xref ref-type="bibr" rid="bib40">Lee et al., 2009</xref>; <xref ref-type="bibr" rid="bib57">Noack and Miossec, 2014</xref>). In general, nTreg cells are dominant in the periphery under unperturbed conditions, whereas iTreg cells are often boosted upon special immune challenges to balance inflammatory responses (<xref ref-type="bibr" rid="bib56">Murai et al., 2010</xref>). Furthermore, enhancing iTreg cells by stimulating iTreg differentiation or employing adoptive transfer appeared to be effective in the therapeutic treatment for several immune diseases (<xref ref-type="bibr" rid="bib10">Dall'Era et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Esensten et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Göschl et al., 2019</xref>; <xref ref-type="bibr" rid="bib64">Ryba-Stanisławowska et al., 2019</xref>).</p><p>iTreg cells are derived from activated T (Th0) cells, which can also differentiate into effector CD4<sup>+</sup> T cells (Teffs), including Th1, Th2, and Th17, depending on cytokine contexts, and the establishment of iTreg cells relies on transforming growth factor β1 (TGFβ1) (<xref ref-type="bibr" rid="bib5">Chen et al., 2003</xref>; <xref ref-type="bibr" rid="bib48">Maciolek et al., 2014</xref>). It has been characterized that TGFβ1 stimulates the phosphorylation of transcription factors Smad2 and Smad3 to facilitate the formation of a heterotrimeric complex containing Smad2/3/4 (<xref ref-type="bibr" rid="bib14">Derynck and Zhang, 2003</xref>; <xref ref-type="bibr" rid="bib73">Souchelnytskyi et al., 1997</xref>). Subsequently, this Smad2/3/4 complex binds to the conservative non-coding sequence 1 (CNS1) in <italic>Foxp3,</italic> which encodes the master transcription factor critical for the establishment and maintenance of iTreg cells, thereby promoting iTreg differentiation (<xref ref-type="bibr" rid="bib6">Chen et al., 2011</xref>; <xref ref-type="bibr" rid="bib20">Fontenot et al., 2003</xref>; <xref ref-type="bibr" rid="bib32">Hori et al., 2003</xref>; <xref ref-type="bibr" rid="bib68">Schlenner et al., 2012</xref>).</p><p>Accumulating evidence has revealed that different types of T cells are usually associated with distinct metabolic characteristics (<xref ref-type="bibr" rid="bib7">Chen et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Kempkes et al., 2019</xref>). For instance, Th0, Th1, Th2, and Th17 prefer de novo fatty acid synthesis (FAS) that substantially supports anabolism to meet the need for biological macromolecules during rapid proliferation (<xref ref-type="bibr" rid="bib46">Lochner et al., 2015</xref>; <xref ref-type="bibr" rid="bib47">Ma et al., 2017</xref>; <xref ref-type="bibr" rid="bib48">Maciolek et al., 2014</xref>; <xref ref-type="bibr" rid="bib78">Wang et al., 2011</xref>). In contrast, iTreg relies on fatty acid oxidation (FAO) (<xref ref-type="bibr" rid="bib7">Chen et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Gerriets et al., 2015</xref>; <xref ref-type="bibr" rid="bib47">Ma et al., 2017</xref>; <xref ref-type="bibr" rid="bib54">Michalek et al., 2011</xref>). Because carnitine palmitoyltransferase 1 (CPT1) is the rate-limiting enzyme in FAO, upregulating CPT1 by its substrate palmitate and downregulating CPT1 by the specific inhibitor etomoxir, respectively, could result in enhancement and impairment in FAO and iTreg differentiation (<xref ref-type="bibr" rid="bib28">Gualdoni et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Michalek et al., 2011</xref>). Obviously, FAS and FAO are reciprocal pathways, only one of which can be dominant in a specific type of T cells (<xref ref-type="bibr" rid="bib21">Foster, 2012</xref>; <xref ref-type="bibr" rid="bib85">Wolfgang and Lane, 2006</xref>). During iTreg differentiation, cell metabolism undergoes a series of dramatic changes, including a shift from FAS to FAO. Although the downregulation of FAS appears to be important (<xref ref-type="bibr" rid="bib4">Berod et al., 2014</xref>), the mechanism regulating FAS in the process of iTreg differentiation is still unclear.</p><p>FAS is directly controlled by a series of metabolic enzymes in cytoplasm, including three rate-limiting enzymes ATP-citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FASN) (<xref ref-type="bibr" rid="bib46">Lochner et al., 2015</xref>). In brief, ACLY converts mitochondrial-derived citrate into acetyl-CoA and oxaloacetic acid (OAA), and provides the main acetyl-CoA source for de novo FAS. ACC catalyzes acetyl-CoA into malonyl-CoA to provide an active two-carbon-unit donor for carbon chain extension. FASN uses both malonyl-CoA and acetyl-CoA as substrates to continuously synthesize long-chain fatty acids. Although regulation of the three enzymes at the transcriptional level was reported (<xref ref-type="bibr" rid="bib38">Kidani et al., 2013</xref>), direct modulation of their activities by posttranslational modifications (PTMs), particularly ubiquitination that is tightly coupled with protein degradation, has set a new stage for the exploration of FAS control. For instance, nutrient deficiency induced ACLY ubiquitination at K540/K546/K554 in human lung cancer cells. This change resulted in the degradation of ACLY proteins and suppressed de novo lipid synthesis, eventually causing impairment in cell proliferation (<xref ref-type="bibr" rid="bib42">Lin et al., 2013</xref>; <xref ref-type="bibr" rid="bib88">Zhang et al., 2016</xref>). ACC stability as well as de novo lipid synthesis in mouse adipocytes was found to be regulated by ubiquitination (<xref ref-type="bibr" rid="bib62">Qi et al., 2006</xref>). Additionally, FASN ubiquitination in HEK293T cells was also linked to its degradation, which in turn compromised de novo lipid synthesis (<xref ref-type="bibr" rid="bib43">Lin et al., 2016</xref>). However, it still remains poorly understood whether and how ubiquitination is involved in the control of FAS during iTreg differentiation.</p><p>In this study, we have revealed that ACLY activity declined significantly as iTreg cells were differentiated. Upregulation in ACLY expression hindered the switch from FAS to FAO and thereby impaired iTreg differentiation. ACLY-dependent malonyl-CoA, an intermediate in FAS, could directly finetune CPT1 activity and therefore FAO. In response to TGFβ1 stimulation, CUL3-KLHL25 mediated ACLY ubiquitination to facilitate its degradation. When we removed CUL3 to block ACLY degradation, iTreg differentiation and colitis alleviation by adoptive iTreg cells in mice were compromised. Simultaneous depletion of ACLY partially rescued CUL3 deficiency-induced defects in iTreg differentiation and colitis alleviation. Overall, we demonstrated the regulation of iTreg differentiation via TGFβ1-CUL3-KLHL25-ACLY axis and bring insights into the maintenance of immune homeostasis for the prevention of colitis.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>ACLY is critical for the efficient differentiation of iTreg cells</title><p>To understand the alteration in FAS during iTreg differentiation, we examined the three rate-limiting enzymes ACLY, ACC, and FASN in FAS pathway. It appeared that the enzymatic activity of ACLY was reduced markedly, while ACC and FASN activities remained largely unchanged (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Meanwhile, acetyl-CoA and OAA, the two products of ACLY-mediated reaction, were also reduced upon TGFβ1 treatment, confirming the decreased ACLY activity during iTreg differentiation (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Importantly, preventing the decline in ACLY activity by supplementing cells with exogenous ACLY drastically impaired iTreg differentiation (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). In contrast, knocking down <italic>Acly</italic> by small interfering RNAs (siRNAs) or blocking ACLY activity by the specific inhibitor SB204990 led to elevated iTreg differentiation (<xref ref-type="fig" rid="fig1">Figure 1D–E</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D-E</xref>). Together, these data suggest that ACLY regulates iTreg differentiation.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>ACLY is critical for iTreg cell differentiation.</title><p>(<bold>A, B</bold>) Detection of ATP-citrate lyase (ACLY) activity in inducible regulatory T (iTreg) cells. Naive CD4<sup>+</sup> T cells isolated from mice were cultured with Dynabeads Mouse T-Activator CD3/CD28 and rmIL-2 for 72 hr to obtain activated T (Th0) cells or simultaneously supplemented with rhTGFβ1 (2 ng/ml) to generate iTreg cells. (<bold>A</bold>) Assessment of enzymatic activity for ACLY, acetyl-CoA carboxylase (ACC), and fatty acid synthase (FASN) from Th0 or iTreg cells. (<bold>B</bold>) Assay for cytosol acetyl-CoA and oxaloacetic acid (OAA) from Th0 or iTreg cells. (<bold>C</bold>) ACLY overexpression affects iTreg differentiation. Naive CD4<sup>+</sup> T cells were transfected with GFP-ACLY and cultured under Th0- or iTreg-polarization condition as in (<bold>A</bold>). Cells were analyzed by flow cytometry (FCM) to evaluate GFP<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> iTreg cells. (<bold>D, E</bold>) Inhibition of ACLY influences iTreg differentiation. Naive CD4<sup>+</sup> T cells transfected with small interfering RNAs (siRNAs) against <italic>Acly</italic> (<bold>D</bold>) or treated with SB204990 (100 μM) (<bold>E</bold>) were cultured under Th0- or iTreg (with 0.5 ng/ml rhTGFβ1)-polarization condition for 72 hr. CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> iTreg cells were assayed by FCM (left) and quantified (right). Data represent mean ± SD of three independent experiments, with significance determined by Student's t-test (<bold>A, B</bold>) or one-way analysis of variance (ANOVA) test (<bold>C–E</bold>). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001; ns, nonsignificant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Analyses of ACLY activity during iTreg differentiation.</title><p>(<bold>A</bold>) Activated T (Th0) and inducible regulatory T (iTreg) cell polarization in vitro. Naive CD4<sup>+</sup> T cells isolated from mice were cultured with Dynabeads Mouse T-Activator CD3/CD28 and rmIL-2 for 72 hr to obtain Th0 cells or simultaneously supplemented with rhTGFβ1 (2 ng/ml) to generate iTreg cells. CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> iTreg cells were evaluated by flow cytometry (FCM). (<bold>B</bold>) Isolation of cytosolic fraction. Cytosolic fraction without mitochondria and nuclei was isolated from cells prepared as in (<bold>A</bold>). (<bold>C</bold>) Enzymatic activity of ATP-citrate lyase (ACLY). Cells were transfected with GFP-ACLY and cultured as in (<bold>A</bold>) for 24 hr. Enzymatic activity of ACLY was measured and quantified. (<bold>D, E</bold>) Assay for ACLY activity in cells treated with si<italic>Acly</italic> or SB204990. Cells transfected with small interfering RNA (siRNA) against <italic>Acly</italic> (<bold>D</bold>) or treated with SB204990 (100 μM) (<bold>E</bold>) were induced under Th0- or iTreg (with 0.5 ng/ml transforming growth factor β1 [TGFβ1])-polarization condition for 24 hr as in <xref ref-type="fig" rid="fig1">Figure 1E</xref> prior to the measurement of enzymatic activity of ACLY. (<bold>A, B</bold>) One representative experiment out of three independent experiments is represented. (<bold>C–E</bold>) Data represent mean ± SD based on three independent experiments, with significance determined by one-way analysis of variance (ANOVA) test. *p&lt;0.05, **p&lt;0.01.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>ACLY is required for the reprogramming of fatty acid metabolism during iTreg differentiation</title><p>ACLY converts citrate into acetyl-CoA and OAA, and acetyl-CoA is the main source supporting de novo FAS, mevalonate-cholesterol synthesis, and histone acetylation (<xref ref-type="bibr" rid="bib87">Zaidi et al., 2012</xref>). To further understand ACLY-dependent regulation of metabolic reprogramming during iTreg differentiation, we performed [U-<sup>13</sup>C] glucose-tracing experiment. Upon ACLY inhibition, <sup>13</sup>C-labeled fatty acids were reduced as expected (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). However, key intermediates in mevalonate-cholesterol synthesis, including 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA), mevalonate, mevalonate 5-pyrophosphate, and cholesterol remained rather stable irrespective of the presence of ACLY inhibitor (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–D</xref>). Exogenous supplement of mevalonate and cholesterol failed to affect ACLY-inhibition-induced enhancement in iTreg differentiation (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A–C</xref>), confirming a dispensable role of mevalonate-cholesterol synthesis in ACLY-dependent regulation of iTreg differentiation. Meanwhile, we examined the level of nuclear acetyl-CoA that directly supports histone acetylation and found that it remained relatively stable, regardless of the presence of ACLY inhibitor (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A–B</xref>). In line with this observation, acetylation in total histones and H3/H4 was not influenced by ACLY inhibition (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3C–D</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>ACLY inhibition induces the reprogramming in fatty acid metabolism during iTreg differentiation.</title><p>(<bold>A</bold>) ATP-citrate lyase (ACLY) inhibition reduces de novo fatty acid synthesis (FAS). Naive CD4<sup>+</sup> T cells were treated with SB204990 (100 μM) and cultured under inducible regulatory T (iTreg)-polarization condition as in <xref ref-type="fig" rid="fig1">Figure 1E</xref> for 24 hr in the presence of [U-<sup>13</sup>C] glucose (11 mM). Cells were collected and subjected to metabolic flux analysis for FAS by ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS) analysis. n = 4, Student's t-test, mean ± SD. *p&lt;0.05, **p&lt;0.01, ****p&lt;0.0001; ns, nonsignificant. (<bold>B, C</bold>) Functional evaluation of metabolic intermediates from FAS on iTreg differentiation. Naive CD4<sup>+</sup> T cells were treated with SB204990 (100 μM) and cultured as in <xref ref-type="fig" rid="fig1">Figure 1E</xref> in the presence of different doses of palmitate (<bold>B</bold>) or malonyl-CoA (<bold>C</bold>). CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> iTreg cells were assayed by flow cytometry (FCM) (left) and quantified (right). (<bold>D, E</bold>) ACLY inhibition increases carnitine palmitoyltransferase 1 (CPT1) activity and fatty acid oxidation (FAO). In the presence of malonyl-CoA (50 μM) or cerulenin (4 μM), naive CD4<sup>+</sup> T cells treated with SB204990 were cultured as in <xref ref-type="fig" rid="fig1">Figure 1E</xref> for 24 hr. Cell lysates were used for analyzing CPT1 activity (<bold>D</bold>). For oxygen consumption rate (OCR) detection, cells were transferred to XF Base Medium containing palmitate and carnitine. Diagram (left) illustrating the OCR at various conditions and associated quantifications (right) are shown (<bold>E</bold>). (<bold>F</bold>) Impact of <italic>Cpt1</italic> knockdown on iTreg differentiation. Naive CD4<sup>+</sup> T cells transfected with small interfering RNA (siRNA) against <italic>Cpt1</italic> were cultured as in <xref ref-type="fig" rid="fig1">Figure 1E</xref>. CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> iTreg cells were assayed by FCM (left) and quantified (right). (<bold>B–F</bold>) Data represent mean ± SD of three (<bold>D–F</bold>) or four (<bold>B, C</bold>) independent experiments, with significance determined by one-way analysis of variance (ANOVA) test. **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001; ns, nonsignificant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Detection of metabolic intermediates in mevalonate-cholesterol synthesis pathway upon ACLY inhibition.</title><p>(<bold>A–D</bold>) Naive CD4<sup>+</sup> T cells treated with SB204990 were cultured under inducible regulatory T (iTreg)-polarization condition as in <xref ref-type="fig" rid="fig1">Figure 1E</xref>. Cells were lysed for the detection of HMG-CoA (<bold>A</bold>), mevalonate (<bold>B</bold>), and mevalonate-5-pyrophosphate (<bold>C</bold>) by enzyme-linked immunosorbent assay (ELISA) or stained by Filipin III for evaluating cholesterol by flow cytometry (FCM) (<bold>D</bold>). Data represent mean ± SD of four independent experiments, with significance determined by Student's t-test. ns, nonsignificant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Impact of mevalonate and cholesterol on iTreg differentiation.</title><p>(<bold>A, B</bold>) Assay for mevalonate and cholesterol. Naive CD4<sup>+</sup> T cells were cultured under inducible regulatory T (iTreg)-polarization condition as in <xref ref-type="fig" rid="fig1">Figure 1E</xref> for 24 hr in the presence of variable doses of mevalonate (<bold>A</bold>) or cholesterol (<bold>B</bold>). Levels of mevalonate (<bold>A</bold>) or cholesterol (<bold>B</bold>) were evaluated by enzyme-linked immunosorbent assay (ELISA) and flow cytometry (FCM), respectively. (<bold>C</bold>) Influence from mevalonate and cholesterol on ATP-citrate lyase (ACLY)-inhibition-induced iTreg differentiation. Naive CD4<sup>+</sup> T cells were cultured as in <xref ref-type="fig" rid="fig1">Figure 1E</xref> in the presence of different doses of mevalonate or cholesterol for 72 hr. Subsequently, CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> iTreg cells were analyzed by FCM (left) and quantified (right). (<bold>A–C</bold>) Data represent mean ± SD of three (<bold>A, B</bold>) or four (<bold>C</bold>) independent experiments, with significance determined by one-way analysis of variance (ANOVA) test. **p&lt;0.01, ****p&lt;0.0001; ns, nonsignificant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Examination of nuclear acetyl-CoA and histone acetylation upon ACLY inhibition.</title><p>(<bold>A–D</bold>) Cells prepared as in <xref ref-type="fig" rid="fig1">Figure 1E</xref> for 24 hr were fractionated (<bold>A</bold>) and evaluated for nuclear acetyl-CoA (<bold>B</bold>). Acetylation in total histones (<bold>C</bold>) and H3/H4 from whole-cell lysates (<bold>D</bold>) were assessed. (<bold>B–D</bold>) Quantification shows mean ± SD based on three independent experiments, with significance determined by Student's t-test. ns, nonsignificant. For western blot (WB) in (<bold>A), (C), and (D</bold>), one representative experiment out of three is represented. Associated scores indicate mean intensities based on three biological replicas.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Functional comparison between ACC and FASN in ACLY-inhibition-induced iTreg differentiation.</title><p>(<bold>A</bold>) Assay for palmitate in cells. Naive CD4<sup>+</sup> T cells were cultured under inducible regulatory T (iTreg)-polarization condition as in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> for 24 hr in the presence of variable doses of Bodipy-palmitate prior to flow cytometry (FCM) evaluation (left) and quantification (right). (<bold>B</bold>) Fatty acid synthesis (FAS) and fatty acid oxidation (FAO) pathways. (<bold>C</bold>) Assay of iTreg differentiation upon acetyl-CoA carboxylase (ACC) or fatty acid synthase (FASN) inhibition. Naive CD4<sup>+</sup> T cells were cultured as in <xref ref-type="fig" rid="fig1">Figure 1E</xref>. In the presence of variable doses of ACC inhibitor (PF05175157) or FASN inhibitor (cerulenin), cells positive for CD4/CD25/Foxp3 were evaluated with FCM (left) and quantified (right). (<bold>D</bold>) Analysis of malonyl-CoA level upon ATP-citrate lyase (ACLY) inhibition. Naive CD4<sup>+</sup> T cells cultured as in <xref ref-type="fig" rid="fig1">Figure 1E</xref> for 24 hr were analyzed for malonyl-CoA by high-performance liquid chromatography (HPLC). (<bold>A, C, D</bold>) Data represent mean ± SD of three independent experiments, with significance determined by one-way analysis of variance (ANOVA) test (<bold>A, C</bold>) or Student's t-test (<bold>D</bold>). *p&lt;0.05, **p&lt;0.01, and ****p&lt;0.0001; ns, nonsignificant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig2-figsupp4-v1.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 5.</label><caption><title>Functional evaluation of CPT1 in ACLY-inhibition-induced iTreg differentiation.</title><p>(<bold>A</bold>) Assay of malonyl-CoA level. Naive CD4<sup>+</sup> T cells were cultured as in <xref ref-type="fig" rid="fig1">Figure 1E</xref> for 24 hr in the presence of malonyl-CoA (50 μM) or cerulenin (4 μM), and malonyl-CoA level was analyzed by high-performance liquid chromatography (HPLC). (<bold>B</bold>) Impact of carnitine palmitoyltransferase 1 (CPT1) inhibition on inducible regulatory T (iTreg) differentiation. Naive CD4<sup>+</sup> T cells were cultured as in <xref ref-type="fig" rid="fig1">Figure 1E</xref> in the presence of etomoxir (5 μM). CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> iTreg cells were analyzed by flow cytometry (FCM) (left) and quantified (right). Data represent mean ± SD of three independent experiments, with significance determined by one-way analysis of variance (ANOVA) test. **p&lt;0.01, ***p&lt;0.001; ns, nonsignificant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig2-figsupp5-v1.tif"/></fig></fig-group><p>Intriguingly, adding back palmitate did not change ACLY-inhibition-induced iTreg differentiation (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A</xref>), despite a significant reduction in FAS upon ACLY inhibition (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Considering that palmitate, the terminal product of FAS, may not be the limiting factor coordinating ACLY-dependent impact and iTreg differentiation, other intermediate products in FAS can be potentially at play (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B</xref>). Next, we targeted key enzymes in FAS separately with different inhibitors to gain insights into the pivotal metabolite(s). While FASN inhibition abolished ACLY-inhibition-induced iTreg differentiation, the inhibition of ACC barely had any effect (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4C</xref>). This strongly indicates that malonyl-CoA, the substrate of FASN, might be important for ACLY-inhibition-induced iTreg differentiation. Upon ACLY inhibition, we did observe a clear reduction in malony-CoA (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4D</xref>). More importantly, add-back of malonyl-CoA completely abolished ACLY-inhibition-induced iTreg differentiation (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). These data suggest that ACLY-dependent regulation of iTreg differentiation is probably through malonyl-CoA.</p><p>Because malonyl-CoA is a well-characterized metabolic intermediate capable of inhibiting CPT1, the key enzyme in FAO, we asked whether ACLY inhibition could regulate CPT1 activity and thereby FAO to promote iTreg differentiation (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B</xref>). When ACLY was inhibited by SB204990, both CPT1 activity (<xref ref-type="fig" rid="fig2">Figure 2D</xref>) and FAO (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) were enhanced. Under the same condition, upregulating the cellular level of malonyl-CoA by exogenous supplementation of malonyl-CoA or FASN inhibition abrogated ACLY-inhibition-induced upregulation in CPT1 activity (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5A</xref>) and FAO (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Importantly, knockdown or inhibition of CPT1 abolished ACLY-inhibition-induced iTreg differentiation (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5B</xref>). Collectively, the reduction in malonyl-CoA resulted from ACLY inhibition mediates the derepression of CPT1 to facilitate FAO and iTreg differentiation.</p></sec><sec id="s2-3"><title>TGFβ1 induces ACLY ubiquitination and degradation during iTreg differentiation</title><p>To further understand the decline in ACLY activity during iTreg differentiation, we first isolated ACLY proteins from Th0 and iTreg cells and normalized them to the same level (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A–B</xref>). Interestingly, both ACLY activity and Ser455 phosphorylation, which is a marker directly reflecting the enzymatic activity of ACLY (<xref ref-type="bibr" rid="bib11">Das et al., 2015</xref>; <xref ref-type="bibr" rid="bib72">Sivanand et al., 2017</xref>), remained unchanged (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A–B</xref>). However, a dramatic decrease in ACLY protein, but not in its mRNA, was observed in the process of iTreg differentiation (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>), strongly arguing a mechanism regulating ACLY at its protein level.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>TGFβ1 induces ACLY ubiquitination and degradation during iTreg differentiation.</title><p>(<bold>A</bold>) Assay of ATP-citrate lyase (ACLY) protein level. Activated T (Th0) and inducible regulatory T (iTreg) cells prepared as in <xref ref-type="fig" rid="fig1">Figure 1A</xref> were subjected to western blot (WB) with antibodies against ACLY (left). Quantification of ACLY levels (right). (<bold>B</bold>) Impact of transforming growth factor β1 (TGFβ1) on ACLY degradation. Naive CD4<sup>+</sup> T cells were cultured as in <xref ref-type="fig" rid="fig1">Figure 1A</xref> for 24 hr and treated with cycloheximide (CHX) (10 μg/ml) as indicated prior to WB analysis (left). Quantification of ACLY levels (right). (<bold>C</bold>) Pathway analysis for ACLY degradation. Th0 and iTreg cells polarized as in <xref ref-type="fig" rid="fig1">Figure 1A</xref> for 24 hr were treated with MG132 (left) or leupeptin (right) and analyzed with WB for ACLY protein. (<bold>D, E</bold>) Impact of TGFβ1 on ACLY ubiquitination. Cells polarized as in <xref ref-type="fig" rid="fig1">Figure 1A</xref> for 24 hr were treated with MG132 (10 μM) and cell extracts were immunoprecipitated with antibodies against ACLY (<bold>D</bold>) or ubiquitin (Ub) (<bold>E</bold>). IgG serves as a negative control. (<bold>F–H</bold>) Functional comparison between ACLY<sup>WT</sup> and ACLY<sup>3KR</sup>. Naive CD4<sup>+</sup> T cells transfected with GFP-ACLY<sup>WT</sup> or -ACLY<sup>3KR</sup> were polarized as in <xref ref-type="fig" rid="fig1">Figure 1A</xref> for 24 hr. (<bold>F</bold>) Extracts from cells pre-treated with MG132 were assayed with immunoprecipitation (IP) for ACLY ubiquitination. IgG serves as a negative control. (<bold>G</bold>) WB analysis for ACLY protein. (<bold>H</bold>) Cell lysates were prepared for the analysis of carnitine palmitoyltransferase 1 (CPT1) activity. (<bold>I</bold>) ACLY ubiquitination impacts on iTreg differentiation. Cells transfected with GFP-ACLY<sup>WT</sup> or -ACLY<sup>3KR</sup> were polarized as in <xref ref-type="fig" rid="fig1">Figure 1A</xref> and assessed with flow cytometry (FCM) (left). Quantification of GFP<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> iTreg cells (right). (<bold>A–C, G–I</bold>) Quantification shows mean ± SD based on three independent experiments. Student's t-test (<bold>A</bold>), two-way analysis of variance (ANOVA) test (<bold>B</bold>), or one-way ANOVA test (<bold>C, G–I</bold>) was used. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001; ns, nonsignificant. For WB in (<bold>A–G</bold>), one representative experiment out of three is represented. Associated scores indicate mean intensities based on three biological replicas.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Assessment of ACLY activity and mRNA in Th0 and iTreg cells.</title><p>(<bold>A, B</bold>) Analysis of ATP-citrate lyase (ACLY) enzymatic activity. Same amount of ACLY from activated T (Th0) or inducible regulatory T (iTreg) cells that were prepared as in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> was used in assays for detecting enzymatic activity (<bold>A</bold>) and ACLY phosphorylation at S455 (<bold>B</bold>). (<bold>C</bold>) Analysis of <italic>Acly</italic> mRNA. Cells prepared as in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> were examined for ACLY transcription by reverse transcription polymerase chain reaction (RT-PCR). (<bold>A–C</bold>) Quantification shows mean ± SD based on three independent experiments, with significance determined by Student's t-test. ns, nonsignificant. For western blot (WB) in (<bold>A) and (B</bold>), one representative experiment out of three is represented. Associated scores indicate mean intensities based on three biological replicas.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>K530/536/544 are important for ACLY degradation.</title><p>(<bold>A</bold>) Conservative analysis of ATP-citrate lyase (ACLY) amino acid sequence. (<bold>B</bold>) Time-course analysis for ACLY<sup>WT</sup> and ACLY<sup>3KR</sup> degradation. Cells transfected with GFP-ACLY<sup>WT</sup> or -ACLY<sup>3KR</sup> were induced under inducible regulatory T (iTreg)-polarization condition as in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> for 24 hr and treated with cycloheximide (CHX) (10 μg/ml) prior to the analysis of exogenous ACLY by western blotting (WB). Quantification shows mean ± SD based on three independent experiments, with significance determined by one-way analysis of variance (ANOVA) test. *p&lt;0.05, ***p&lt;0.001; ns, nonsignificant. For WB, one representative experiment out of three is represented. Associated scores indicate mean intensities based on three biological replicas.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig3-figsupp2-v1.tif"/></fig></fig-group><p>Given that protein levels are controlled by both synthesis and degradation, we next examined ACLY protein level upon the treatment of cycloheximide (CHX), a well-documented ribosome inhibitor, often used for blocking protein synthesis (<xref ref-type="bibr" rid="bib69">Schneider-Poetsch et al., 2010</xref>). Our time-course analysis showed that TGFβ1 stimulation caused a reduction in ACLY protein even in the presence of CHX (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), indicating that protein degradation played an important role in TGFβ1-mediated ACLY downregulation. Indeed, when we blocked protein degradation with MG132, which inhibits ubiquitination-proteasome degradation (<xref ref-type="bibr" rid="bib45">Liu et al., 2016</xref>), TGFβ1-induced downregulation in ACLY was abolished (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). In contrast, the addition of leupeptin, which blocks autophagy-lysosome degradation (<xref ref-type="bibr" rid="bib45">Liu et al., 2016</xref>), did not affect ACLY protein level (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). These results suggested that, during iTreg differentiation, TGFβ1 induced ACLY downregulation via ubiquitination-proteasome degradation.</p><p>Subsequently, we carried on confirming whether ubiquitination determined ACLY stability during iTreg differentiation. In response to TGFβ1 stimulation, ACLY ubiquitination was evidently increased (<xref ref-type="fig" rid="fig3">Figure 3D–E</xref>). Mutation of ACLY at K530, K536, and K544 (3KR), which are homologous to the three ubiquitination sites (K540, K546, and K554) reported in human ACLY (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>; <xref ref-type="bibr" rid="bib42">Lin et al., 2013</xref>; <xref ref-type="bibr" rid="bib88">Zhang et al., 2016</xref>), abolished TGFβ1-dependent upregulation in ACLY ubiquitination (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Importantly, the reduction of ACLY stimulated by TGFβ1 was blocked when K530, K536, and K544 were mutated (<xref ref-type="fig" rid="fig3">Figure 3G</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>). As a consequence, TGFβ1-induced increase in CPT1 activity and iTreg differentiation were diminished (<xref ref-type="fig" rid="fig3">Figure 3H–I</xref>). Together, TGFβ1 promotes ACLY ubiquitination at K530, K536, and K544 to induce ACLY degradation, which in turn facilitates iTreg differentiation.</p></sec><sec id="s2-4"><title>CUL3-KLHL25 is responsible for TGFβ1-mediated ACLY ubiquitination</title><p>In human cells, ACLY ubiquitination was found to be regulated by ubiquitin ligases UBR4 and CUL3-KLHL25 and deubiquitinase USP13 (<xref ref-type="bibr" rid="bib30">Han et al., 2016</xref>; <xref ref-type="bibr" rid="bib42">Lin et al., 2013</xref>; <xref ref-type="bibr" rid="bib88">Zhang et al., 2016</xref>). To substantiate the determinants for ACLY ubiquitination in iTreg cells, we examined which of these candidate regulators interacted with ACLY. CUL3-KLHL25 and USP13, but not UBR4, appeared to interact with ACLY in iTreg cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–B</xref>). Importantly, co-immunoprecipitation demonstrated that CUL3-KLHL25 association, rather than USP13 interaction, with ACLY was dramatically changed by TGFβ1 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). This strongly suggested an important role for CUL3-KLHL25 in TGFβ1-dependent ACLY ubiquitination during iTreg differentiation.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>CUL3-KLHL25 is responsible for TGFβ1-mediated ACLY ubiquitination.</title><p>(<bold>A</bold>) Assay of ATP-citrate lyase (ACLY) interaction with CUL3-KLHL25. Cells polarized as in <xref ref-type="fig" rid="fig1">Figure 1A</xref> for 24 hr were treated with MG132 and assayed by immunoprecipitation (IP) with ACLY antibody. IgG serves as a negative control. (<bold>B–E</bold>) Functional assessment of CUL3-KLHL25 depletion in inducible regulatory T (iTreg) differentiation. Naive CD4<sup>+</sup> T cells transfected with desired small interfering RNAs (siRNAs) were polarized as in <xref ref-type="fig" rid="fig1">Figure 1A</xref> for 24 hr (<bold>B–D</bold>) or 72 hr (<bold>E</bold>). They were pre-treated with MG132 before IP for the detection of ACLY ubiquitination (<bold>B</bold>), analyzed by western blotting (WB) with indicated antibodies (<bold>C</bold>), evaluated for carnitine palmitoyltransferase 1 (CPT1) activity (<bold>D</bold>), and stained for CD4/CD25/Foxp3 to identify iTreg cells prior to flow cytometry (FCM) analysis (<bold>E</bold>). (<bold>F–H</bold>) Functional assays for ACLY ubiquitination in cells derived from <italic>Cul3</italic> knockout mice. Naive CD4<sup>+</sup> T cells isolated from wild-type (WT) or <italic>Cd4<sup>Cre</sup>Cul3<sup>fl/fl</sup></italic> mice were polarized as in <xref ref-type="fig" rid="fig1">Figure 1A</xref> for 24 hr. Cells were pre-treated with MG132 before IP with antibodies against ACLY (<bold>F</bold>) or ubiquitin (Ub) (<bold>G</bold>), or analyzed for ACLY expression with WB (<bold>H</bold>). (<bold>I, J</bold>) Impact of CUL3 deficiency on fatty acid oxidation (FAO) and iTreg differentiation. Naive CD4<sup>+</sup> T cells transfected with siRNAs were induced as in <xref ref-type="fig" rid="fig1">Figure 1A</xref> for 24 hr (<bold>I</bold>) or 72 hr (<bold>J</bold>). Cells were lysed for CPT1 activity detection (<bold>I</bold>) or stained for CD4/CD25/Foxp3 to identify iTreg cells prior to FCM analysis (<bold>J</bold>). (<bold>C–E, H–J</bold>) Quantification shows mean ± SD based on three independent experiments, with significance determined by one-way analysis of variance (ANOVA) test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001; ns, nonsignificant. For WB in (<bold>A–D, F–I</bold>), one representative experiment out of three is represented. Associated scores indicate mean intensities based on three biological replicas.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Examination of ACLY association with ubiquitin ligases and deubiquitinase.</title><p>(<bold>A, B</bold>) Co-immunoprecipitation (co-IP) for ATP-citrate lyase (ACLY) association with USP13, CUL3, KLHL25, and UBR4. Naive CD4<sup>+</sup> T cells were polarized under inducible regulatory T (iTreg)-polarization condition as in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> for 24 hr and pre-treated with MG132 (10 μM) before co-IP with antibodies against ACLY (<bold>A</bold>), USP13, CUL3, or UBR4 (<bold>B</bold>). IgG serves as a negative control. (<bold>C</bold>) Impact of transforming growth factor β1 (TGFβ1) on CUL3 binding to ACLY. Cells polarized as in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> for 24 hr were pre-treated with MG132 before CUL3 IP and western blotting (WB). IgG serves as a negative control. (<bold>A–C</bold>) One representative experiment out of three is represented. Associated scores indicate mean intensities based on three biological replicas.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Knockdown of CUL3-KLHL25 blocks TGFβ1-induced ACLY degradation.</title><p>(<bold>A</bold>) Analysis of si<italic>Klhl25</italic> knockdown efficiency. Cells transfected with indicated small interfering RNAs (siRNAs) (#1, #2, #3, or Mix) were polarized under inducible regulatory T (iTreg)-polarization condition as in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> for 24 hr prior to western blot (WB) analysis and quantification. (<bold>B</bold>) Time-course analysis for ATP-citrate lyase (ACLY) degradation upon knocking down <italic>Cul3</italic> or <italic>Klhl25</italic>. Cells transfected with indicated siRNAs were induced as in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> for 24 hr and were treated with cycloheximide (CHX) (10 μg/ml) prior to WB analysis with antibody against ACLY. (<bold>C</bold>) Analysis of malonyl-CoA level. Cells transfected with siRNAs were polarized as in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> for 24 hr and analyzed for malonyl-CoA by high-performance liquid chromatography (HPLC). (<bold>A–C</bold>) Quantification shows mean ± SD based on three independent experiments, with significance determined by one-way analysis of variance (ANOVA) test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001; ns, nonsignificant. For WB in (<bold>A, B</bold>), one representative experiment out of three is represented. Associated scores indicate mean intensities based on three biological replicas.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Analysis of Treg number in the intestines of <italic>Cd4<sup>Cre</sup>Cul3<sup>fl/fl</sup></italic> mice.</title><p>(<bold>A, B</bold>) Genotype identification of <italic>Cd4<sup>Cre</sup>Cul3<sup>fl/fl</sup></italic> mice. Genotype analyses for (<bold>A</bold>) <italic>Cd4<sup>Cre</sup></italic> and (<bold>B</bold>) <italic>Cul3<sup>fl/fl</sup></italic> mutant genes. Mouse tail DNA was extracted for genotype analysis (<italic>Cd4<sup>Cre</sup></italic> and <italic>Cul3<sup>fl/fl</sup></italic>) with polymerase chain reaction (PCR) and agarose gel electrophoresis. (<bold>C</bold>) Analysis of regulatory T (Treg) cell number in the intestines of <italic>Cd4<sup>Cre</sup>Cul3<sup>fl/fl</sup></italic> mice. Colon lamina propria cells from wild-type (WT) and <italic>Cd4<sup>Cre</sup>Cul3<sup>fl/fl</sup></italic> mice were isolated and frequency of CD4<sup>+</sup>Foxp3<sup>+</sup> Treg was analyzed by flow cytometry (FCM). (<bold>D</bold>) Assay for malonyl-CoA. Naive CD4<sup>+</sup> T cells isolated from WT and <italic>Cd4<sup>Cre</sup>Cul3<sup>fl/fl</sup></italic> mice were transfected with small interfering RNA (siRNA) against <italic>Acly</italic> and induced as described in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> for 24 hr prior to detection of malonyl-CoA by high-performance liquid chromatography (HPLC). (<bold>A, B</bold>) One representative experiment out of three independent experiments is represented. (<bold>C, D</bold>) Quantification shows mean ± SD based on three independent experiments, with significance determined by Student's t-test (<bold>C</bold>) and one-way analysis of variance (ANOVA) test (<bold>D</bold>). *p&lt;0.05, ****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig4-figsupp3-v1.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Functional analysis of ACLY ubiquitination for iTreg cells.</title><p>(<bold>A</bold>) Assay for the expression of surrogate molecules associated with regulatory T (Treg) suppressive activity. Naive CD4<sup>+</sup> T cells isolated from wild-type (WT) and <italic>Cd4<sup>Cre</sup>Cul3<sup>fl/fl</sup></italic> mice were transfected with small interfering RNAs (siRNAs) and cultured under inducible regulatory T (iTreg)-polarization condition as in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> prior to staining with antibodies against CD4, CD25, Foxp3, CTLA4, ICOS, IL-10, and TIGIT. By flow cytometry (FCM), CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> iTreg cells were analyzed for CTLA4, ICOS, IL-10, or TIGIT expression (left). Quantification based on mean fluorescence intensity (MFI) is shown (right). (<bold>B</bold>) Analysis of the suppressive activity of Foxp3-YFP iTreg cells under various conditions. Naive CD4<sup>+</sup> T cells separated from <italic>Foxp3<sup>YFP-Cre</sup></italic> mice were transfected with siRNAs against <italic>Acly</italic> and (or) <italic>Cul3</italic> and cultured under iTreg-polarization condition as in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>. Interference efficiency was evaluated by western blotting (WB). Foxp3-YFP-positive cells sorted by FCM were cocultured with naive CD4<sup>+</sup> T cells pre-staining with CellTrace Violet (CTV, 1 μM) in the presence of anti-CD3/CD28 for 3 days. T-cell proliferation was evaluated using FCM. (<bold>A, B</bold>) Quantification shows mean ± SD based on three independent experiments, with significance determined by one-way analysis of variance (ANOVA) test. ****p&lt;0.0001; ns, nonsignificant. For WB in (<bold>B</bold>) and FCM analysis for iTreg in (<bold>A</bold>, <bold>B</bold>), one representative experiment out of three is represented.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig4-figsupp4-v1.tif"/></fig></fig-group><p>It is known that CUL3-KLHL25 complex belongs to Cullin–RING ubiquitin ligase family, the largest class of ubiquitin ligases (<xref ref-type="bibr" rid="bib8">Chen and Chen, 2016</xref>; <xref ref-type="bibr" rid="bib91">Zheng and Shabek, 2017</xref>). In brief, CUL3 is the core scaffolding protein holding the entire complex together, while KLHL25 serves as an adaptor for substrate recognition (<xref ref-type="bibr" rid="bib88">Zhang et al., 2016</xref>). When we knocked down <italic>Cul3</italic> or <italic>Klhl25</italic> with targeting siRNAs, ACLY ubiquitination was dramatically reduced (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). Also, both ACLY ubiquitination and degradation induced by TGFβ1 were blocked upon the depletion of CUL3 or KLHL25 (<xref ref-type="fig" rid="fig4">Figure 4B–C</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). Moreover, the removal of CUL3 also resulted in an upregulated malonyl-CoA level (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>), reduced CPT1 activity, and downregulated iTreg differentiation (<xref ref-type="fig" rid="fig4">Figure 4D–E</xref>). Importantly, ACLY depletion partially rescued <italic>Cul3</italic>-knockdown-induced alterations in malonyl-CoA level, CPT1 activity, and iTreg differentiation (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>, <xref ref-type="fig" rid="fig4">Figure 4D–E</xref>). These data demonstrated that TGFβ1-mediated ACLY ubiquitination and degradation rely on CUL3-KLHL25.</p><p>In addition, we generated CD4<sup>+</sup> T-cell-specific CUL3-deficient mice (<italic>Cd4<sup>Cre</sup>Cul3<sup>fl/fl</sup></italic>) by crossing <italic>Cd4<sup>Cre</sup></italic> mice (<xref ref-type="bibr" rid="bib16">Dong et al., 2008</xref>) with <italic>Cul3<sup>fl/fl</sup></italic> mice (<xref ref-type="bibr" rid="bib53">McEvoy et al., 2007</xref>; <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A–B</xref>). Due to the lack of CUL3, the frequency of CD4<sup>+</sup>Foxp3<sup>+ </sup>Treg cells in colon was reduced as expected (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3C</xref>). Notably, when naive CD4<sup>+</sup> T cells from these CUL3-deficient mice were induced into iTreg cells in vitro, both ACLY ubiquitination and degradation induced by TGFβ1 were blocked (<xref ref-type="fig" rid="fig4">Figure 4F–H</xref>). These observations fully recapitulated what we previously found in siRNA-mediated CUL3-depleted cells. More importantly, alterations induced by CUL3 deficiency, including increase in malonyl-CoA level and decrease in CPT1 activity and iTreg differentiation, were dampened by ACLY depletion (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3D</xref>, <xref ref-type="fig" rid="fig4">Figure 4I–J</xref>). Together, TGFβ1 induces CUL3-KLHL25-mediated ACLY ubiquitination and degradation for iTreg differentiation.</p><p>It is worth mentioning that the suppressive function of iTreg cells did not seem to be affected by ACLY ubiquitination and degradation. When we knocked down <italic>Cul3</italic> and/or <italic>Acly</italic> with targeting siRNAs, levels of distinct surrogate molecules typically associated with the suppressive activity of iTreg cells, including CTLA4, ICOS, TIGIT, and IL-10, remained rather stable (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A</xref>). In agreement with this observation, we took the advantage of the available <italic>Foxp3<sup>YFP-Cre</sup></italic> mice (<xref ref-type="bibr" rid="bib61">Priyadharshini et al., 2018</xref>) and induced YFP-iTreg cell differentiation under various conditions in vitro. We found that YFP-iTreg cells lacking CUL3 alone or in combination with ACLY could still retain the potent suppressive function (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4B</xref>). Hence, instead of the suppressive function of iTreg, ACLY ubiquitination and degradation mainly affect iTreg differentiation.</p></sec><sec id="s2-5"><title>CUL3-KLHL25-ACLY ubiquitination axis regulates human iTreg differentiation</title><p>To further corroborate the role of CUL3-KLHL25-mediated ACLY ubiquitination in human iTreg differentiation, we isolated naive CD4<sup>+</sup> T cells from human peripheral blood and induced them into either Th0 or iTreg cells. As expected, the level of ACLY in iTreg dropped significantly as compared with Th0 (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). ACLY overexpression and inhibition resulted in downregulation and upregulation in iTreg differentiation, respectively (<xref ref-type="fig" rid="fig5">Figure 5B–C</xref>). Furthermore, TGFβ1 treatment promoted CUL3-KLHL25 association with ACLY, resulting in ACLY ubiquitination and degradation (<xref ref-type="fig" rid="fig5">Figure 5D–F</xref>). Upon the mutation of K540/546/554 in ACLY (ACLY<sup>3KR</sup>), TGFβ1-induced ACLY ubiquitination and degradation, as well as iTreg differentiation, were remarkably dampened (<xref ref-type="fig" rid="fig5">Figure 5E–G</xref>). Taken together, these data corroborate the important role of CUL3-KLHL25-mediated ACLY ubiquitination in human iTreg differentiation.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>CUL3-KLHL25-ACLY ubiquitination axis regulates human iTreg differentiation.</title><p>(<bold>A</bold>) Assay of ATP-citrate lyase (ACLY) expression in human inducible regulatory T (iTreg) cells. Naive CD4<sup>+</sup> T cells isolated from human peripheral blood were cultured with Dynabeads Human T-Activator CD3/CD28 and rhIL-2 to induce activated T (Th0) cells or simultaneously supplemented with rhTGFβ1 (2 ng/ml) to induce iTreg cells for 24 hr. Cell extracts were subsequently analyzed for ACLY expression by western blotting (WB). (<bold>B</bold>) ACLY overexpression affects iTreg cell differentiation. Human naive CD4<sup>+</sup> T cells transfected with GFP-ACLY<sup>WT</sup> were polarized as in (<bold>A</bold>) for 72 hr prior to the assessment of iTreg cells by flow cytometry (FCM) (left). Quantification of iTreg populations (right). (<bold>C</bold>) ACLY inhibition affects iTreg differentiation. Cells treated with SB204990 were cultured under Th0- or iTreg (with 0.5 ng/ml rhTGFβ1)-polarization condition for 72 hr and subjected to the analysis (left) and quantification (right) of iTreg cells. (<bold>D</bold>) ACLY interaction with CUL3-KLHL25. Cells prepared as in (<bold>A</bold>) were pre-treated with MG132 before immunoprecipitation (IP) with ACLY antibody. IgG serves as a negative control. (<bold>E–G</bold>) ACLY ubiquitination regulates human iTreg differentiation. Cells transfected with GFP-ACLY<sup>WT</sup> or -ACLY<sup>3KR</sup> were induced under Th0- or iTreg-polarization condition as described in (<bold>A</bold>) for 24 hr (<bold>E, F</bold>) or 72 hr (<bold>G</bold>). Cells were pre-treated with MG132 before IP for the assessment of protein ubiquitination (<bold>E</bold>), examined by WB (<bold>F</bold>), or evaluated for GFP/CD25/Foxp3 expression with FCM (left), and quantified (right) (<bold>G</bold>). (<bold>A–C, F, G</bold>) Quantification shows mean ± SD based on three independent experiments, with significance determined by Student's t-test (<bold>A, C</bold>) or one-way analysis of variance (ANOVA) test (<bold>B, F, G</bold>). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001; ns, nonsignificant. For WB in (<bold>A</bold>) and (<bold>D–F</bold>), one representative experiment out of three is represented. Associated scores indicate mean intensities based on three biological replicas.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig5-v1.tif"/></fig></sec><sec id="s2-6"><title>ACLY inhibition alleviates mouse colitis by promoting iTreg cell generation</title><p>As a common digestive system disease, IBD poses a serious threat to public health, and the number of patients with IBD keeps growing (<xref ref-type="bibr" rid="bib3">Bernstein et al., 2010</xref>). Manipulation of iTreg functions holds promise for the therapeutic treatment of IBD (<xref ref-type="bibr" rid="bib9">Clough et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Izcue et al., 2006</xref>; <xref ref-type="bibr" rid="bib76">van Herk and Te Velde, 2016</xref>). Next, we performed a functional assay for CUL3-KLHL25-mediated ACLY ubiquitination in a classic mouse IBD model (<xref ref-type="bibr" rid="bib84">Wirtz and Neurath, 2007</xref>). Same amount of naive CD4<sup>+</sup> T cells was isolated from wild-type (WT) or <italic>Cd4<sup>Cre</sup>Cul3<sup>fl/fl</sup></italic> (<italic>Cul3<sup>-/-</sup></italic>) mice and transfected with siRNAs prior to polarization to obtain Th0 (WT), iTreg (WT), iTreg (<italic>Cul3<sup>-/-</sup></italic>), or iTreg (<italic>Cul3<sup>-/-</sup></italic>+si<italic>Acly</italic>) cells (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Compared to control, the lack of CUL3 impaired iTreg differentiation, while ACLY depletion compromised CUL3-deficiency-induced changes (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>, <xref ref-type="fig" rid="fig6">Figure 6B</xref>). Upon the adoptive transfer of these cells along with WT-mice-derived naive CD4<sup>+</sup> T cells used to induce colitis into <italic>Rag1<sup>-/-</sup></italic> recipient mice (<xref ref-type="fig" rid="fig6">Figure 6A</xref>), Th0 (WT) group suffered serious colitis lying in body weight loss, disease activity index (DAI) score increase, colon length shortening, inflammatory cell infiltration, mucosal edema and injury as well as crypt damage increase (<xref ref-type="fig" rid="fig6">Figure 6C–E</xref>). As expected, iTreg (WT) mice showed significantly alleviated pathological alterations associated with colitis (<xref ref-type="fig" rid="fig6">Figure 6C–E</xref>). When we injected recipient mice with iTreg (<italic>Cul3<sup>-/-</sup></italic>) cells, less alleviation in colitis was observed as compared to that in iTreg (WT) group (<xref ref-type="fig" rid="fig6">Figure 6C–E</xref>). Importantly, knocking down <italic>Acly</italic> in iTreg (<italic>Cul3<sup>-/-</sup></italic>+si<italic>Acly</italic>) cells prior to the adoptive transfer rescued CUL3-deficiency-induced failures in colitis alleviation (<xref ref-type="fig" rid="fig6">Figure 6C–E</xref>). Using the same T-cell adoptive transfer strategy, we found that direct inhibition of ACLY by SB204990, which led to elevation in iTreg population from both mesenteric lymphatic node (MLN) and colonic lamina propria (cLP) and alleviation of dextran sodium sulfate (DSS)-induced colitis (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A–F</xref>), also effectively relieved T-cell-transfer-induced colitis in mice (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3A–E</xref>). Together, these in vivo data confirm the important role of CUL3-KLHL25-mediated ACLY ubiquitination in colitis alleviation.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>ACLY ubiquitination promotes iTreg cell generation and alleviates mouse colitis.</title><p>(<bold>A</bold>) Experimental design. (<bold>B</bold>) Impact of inducible regulatory T (iTreg) cells on T-cell proliferation. Activated T (Th0) (wild-type, WT), iTreg (WT), iTreg (<italic>Cul3<sup>-/-</sup></italic>), and iTreg (<italic>Cul3<sup>-/-</sup></italic>+si<italic>Acly</italic>#1) cells were cocultured with carboxyfluorescein diacetate succinimidyl ester (CFSE)-stained naive CD4<sup>+</sup> T cells and treated with Dynabeads Mouse T-Activator CD3/CD28 for 72 hr. T-cell proliferation was evaluated using flow cytometry (FCM) (left). Quantification analysis for CD4<sup>+</sup> T-cell proliferation (right) based on three independent experiments. One-way analysis of variance (ANOVA) test, mean ± SD. **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001. (<bold>C–E</bold>) Systematic evaluation of colitis in mice adoptively transferred with different cells. (<bold>C</bold>) Body weight (left) and disease activity index (DAI) score (right) based on body weight loss, stool consistency, and blood in the stool were recorded weekly. 7 weeks later, entire colons from mice treated in different ways were removed for length assessment (<bold>D</bold>) and hematoxylin and eosin (H and E) staining, which is used for revealing histopathological changes (<bold>E</bold>). Scale bar, 200 μm. One representative experiment out of four biological replicas is represented. (<bold>C, D</bold>) Data represent mean ± SD (n = 4), with significance determined by two-way ANOVA test (<bold>C</bold>) or one-way ANOVA test (<bold>D</bold>). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>ACLY knockdown influences the differentiation of naive CD4<sup>+</sup> T cells derived from <italic>Cul3</italic> knockout mice.</title><p>Naive CD4<sup>+</sup> T cells isolated from wild-type (WT) and <italic>Cd4<sup>Cre</sup>Cul3<sup>fl/fl</sup></italic> mice were transfected with small interfering RNA (siRNA) against <italic>Acly</italic> and induced as described in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> prior to evaluating CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+ </sup>inducible regulatory T (iTreg) cells by flow cytometry (FCM). One representative experiment out of three independent experiments is represented.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>SB204990 administration elevates iTreg population in vivo and alleviates mice colitis.</title><p>(<bold>A, B</bold>) Mice were supplied with dextran sodium sulfate (DSS) (2%, w/v) in drinking water. Meanwhile, ATP-citrate lyase (ACLY) inhibitor (SB204990, 37.5 mg/kg/d) was administrated once every 2 days by oral gavage. 10 days later, regulatory T (Treg) cells in mesenteric lymph nodes (MLNs) (<bold>A</bold>) and colonic lamina propria (cLP) (<bold>B</bold>) were examined by flow cytometry (FCM). (<bold>C–F</bold>) Systematic evaluation of colitis in mice administrated with ACLY inhibitor. Body weight (<bold>C</bold>) and disease activity index (DAI) score (<bold>D</bold>), based on body weight loss, stool consistency, and blood in the stool, were recorded daily. 10 days later, entire colons from mice treated in different ways were removed for length assessment (<bold>E</bold>) and hematoxylin and eosin (H and E) staining for histopathological changes (<bold>F</bold>). Scale bar, 200 μm. In (<bold>F</bold>), one representative experiment out of three biological replicas is represented. (<bold>A–E</bold>) Data represent mean ± SD (n = 3), with significance determined by one-way analysis of variance (ANOVA) test (<bold>A, B, E</bold>) and two-way ANOVA test (<bold>C, D</bold>). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig6-figsupp2-v1.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>ACLY inhibition promotes iTreg differentiation and relieves mice colitis.</title><p>(<bold>A</bold>) Inhibition of ATP-citrate lyase (ACLY) by SB204990 facilitates inducible regulatory T (iTreg) differentiation. Naive CD4<sup>+</sup> T cells treated with SB204990 were induced as in <xref ref-type="fig" rid="fig1">Figure 1E</xref>. CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> iTreg cells were evaluated by flow cytometry (FCM). (<bold>B</bold>) Assay for iTreg inhibitory function in vitro. Cells prepared as in (<bold>A</bold>) were cocultured with carboxyfluorescein diacetate succinimidyl ester (CFSE)-stained naive CD4<sup>+</sup> T cells in the presence of Dynabeads Mouse T-Activator CD3/CD28 for 72 hr. CD4<sup>+</sup> T-cell proliferation was analyzed by FCM (left) and quantified (right) based on three independent experiments. One-way analysis of variance (ANOVA) test, mean ± SD. **p&lt;0.01. (<bold>C–E</bold>) Systematic evaluation of colitis in mice adoptively transferred with different cells. (<bold>C</bold>) Body weight (left) and disease activity index (DAI) score (right), based on body weight loss, stool consistency, and blood in the stool, were recorded weekly. 7 weeks later, entire colons from mice treated in different ways were removed for length assessment (<bold>D</bold>) and hematoxylin and eosin (H and E) staining for histopathological changes (<bold>E</bold>). Scale bar, 200 μm. (<bold>C, D</bold>) Data represent mean ± SD (n = 4), with significance determined by two-way ANOVA test (<bold>C</bold>) and one-way ANOVA test (<bold>D</bold>). *p&lt;0.05, ***p&lt;0.001, and ****p&lt;0.0001. (<bold>A, E</bold>) One representative experiment out of four biological replicas is represented.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig6-figsupp3-v1.tif"/></fig><fig id="fig6s4" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 4.</label><caption><title>ACLY ubiquitination is involved in the regulation of iTreg differentiation and allergic diarrhea in mice.</title><p>(<bold>A</bold>) Experimental design of the oral allergen-induced food allergy model. (<bold>B</bold>) Analysis of inducible regulatory T (iTreg) differentiation upon ATP-citrate lyase (ACLY) depletion. Naive CD4<sup>+</sup> T cells isolated from wild-type (WT) or <italic>Cd4<sup>Cre</sup>Cul3<sup>fl/fl</sup></italic> mice were transfected with small interfering RNAs (siRNAs) and polarized as described in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>. CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> iTreg cells were evaluated by flow cytometry (FCM). One representative experiment out of three independent experiments is represented. (<bold>C–E</bold>) Systematic evaluation of manifestation of allergic diarrhea in mice adoptively transferred with different cells. (<bold>C</bold>) Frequency of diarrhea in mice challenged with ovalbumin (OVA). Assay of serum OVA-specific IgE (<bold>D</bold>) and mastocyte protease (MCPT-1) (<bold>E</bold>) by enzyme-linked immunosorbent assay (ELISA). (<bold>D, E</bold>) Data represent mean ± SD (n = 4), with significance determined by one-way analysis of variance (ANOVA) test. ***p&lt;0.001, ****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62394-fig6-figsupp4-v1.tif"/></fig></fig-group><p>In addition, we also investigated the role of CUL3-dependent ACLY regulation in an alternative inflammatory disease associated with deregulated Treg function, namely allergic diarrhea (<xref ref-type="bibr" rid="bib39">Kordowski et al., 2019</xref>; <xref ref-type="bibr" rid="bib79">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib86">Yamamoto et al., 2019</xref>). Adoptive transfer of WT iTreg cells, but not CUL3-deficient cells (<italic>Cul3<sup>-/-</sup></italic>), into recipient mice remarkably alleviated the defects associated with ovalbumin (OVA)-induced allergic diarrhea, including upregulation of OVA-specific IgE antibodies and mastocyte protease (MCPT-1) in serum (<xref ref-type="bibr" rid="bib39">Kordowski et al., 2019</xref>; <xref ref-type="fig" rid="fig6s4">Figure 6—figure supplement 4A–E</xref>). Knockdown of <italic>Acly</italic> rescued the effect of CUL3 deficiency on diarrhea (<xref ref-type="fig" rid="fig6s4">Figure 6—figure supplement 4B–E</xref>). Hence, these results suggest an important role for ‘CUL3-ACLY’ axis in the regulation of diarrhea.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>iTreg cells are essential for the regulation of immune homeostasis, and their establishment relies on TGFβ1 induction (<xref ref-type="bibr" rid="bib5">Chen et al., 2003</xref>; <xref ref-type="bibr" rid="bib15">Dominguez-Villar and Hafler, 2018</xref>). Recent findings suggest that a shift from FAS to FAO is required for efficient iTreg differentiation (<xref ref-type="bibr" rid="bib4">Berod et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Michalek et al., 2011</xref>), but the control of this process is still unclear. Here we unveiled a TGFβ1-CUL3-KLHL25-ACLY axis that is important for the metabolic reprogramming in fatty acid metabolism during iTreg differentiation.</p><p>As one of the most well-studied signaling pathways, TGFβ1 governs a number of signaling cascades, including canonical Smad signals and non-canonical MAPK (ERK/JNK/P38), PI3K/Akt, and Rho-like GTPase signals, mainly by regulating different kinases to phosphorylate their downstream factors (<xref ref-type="bibr" rid="bib77">Vander Ark et al., 2018</xref>; <xref ref-type="bibr" rid="bib89">Zhang, 2017</xref>). In the process of iTreg differentiation, TGFβ1 activates TGFRI/II, which are transmembrane protein serine/threonine kinases and directly phosphorylate Smad2/3, to improve Foxp3 expression (<xref ref-type="bibr" rid="bib68">Schlenner et al., 2012</xref>). Interestingly, our work here demonstrated that, through ubiquitination of a key metabolic enzyme, TGFβ1 launched a reprogramming in fatty acid metabolism and promoted iTreg differentiation. These findings indicate ubiquitination as a useful means for TGFβ1 to coordinate fatty acid metabolism and induce iTreg differentiation.</p><p>Moreover, CUL3-KLHL25 is a part of the biggest ubiquitin ligase Cullin-Ring family and is involved in the regulation of numerous biological processes, such as cell cycle regulation, DNA damage responses, and cell apoptosis (<xref ref-type="bibr" rid="bib12">Davidge et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">Genschik et al., 2013</xref>). The lack of CUL3 has been associated with defects in embryogenesis, hypertension, diminished angiogenesis, progressive interstitial inflammation, exacerbated colonic inflammation, and swelled spleens and lymph nodes (<xref ref-type="bibr" rid="bib1">Agbor et al., 2019</xref>; <xref ref-type="bibr" rid="bib41">Li et al., 2017</xref>; <xref ref-type="bibr" rid="bib50">Maekawa et al., 2017</xref>; <xref ref-type="bibr" rid="bib52">Mathew et al., 2012</xref>; <xref ref-type="bibr" rid="bib67">Saritas et al., 2019</xref>; <xref ref-type="bibr" rid="bib71">Singer et al., 1999</xref>). Interestingly, some of these defects, for example, progressive interstitial inflammation, exacerbated colonic inflammation, and swelled spleens and lymph nodes, are clearly relevant to immune system imbalance. In this study, the functional characterization of CUL3-KLHL25 in iTreg differentiation implies that disturbed iTreg cell homeostasis may contribute to CUL3-deficiency-associated defects, in particular, inflammatory-related phenomena. In addition, this may provide a new angle for re-evaluating and understanding severe pathological changes induced by the loss of CUL3.</p><p>It is also worth mentioning that the loss of CUL3 did not affect the differentiation of Th1, Th2, or Th17 in vitro, but enhanced follicular helper T (Tfh) cell number and responses in the germinal center (GC). These observations and our findings suggest that CUL3 may play distinct roles in different types of T cells, such as Tfh and Treg cells. In GC, Tfh cells can be suppressed by follicular regulatory T (Tfr) cells, which are also crucial for the maintenance of immune homeostasis (<xref ref-type="bibr" rid="bib18">Essig et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Huang et al., 2019</xref>). This specific type of T cells is actually derived from Treg cells (<xref ref-type="bibr" rid="bib18">Essig et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Huang et al., 2019</xref>). Whether CUL3 could finetune the balance between Tfh and Tfr for the control of GC function remains to be addressed in future.</p><p>Growing evidence shows that the regulation of cell metabolism is vital for T-cell proliferation, differentiation, and functions (<xref ref-type="bibr" rid="bib23">Galgani et al., 2015</xref>; <xref ref-type="bibr" rid="bib29">Guo, 2017</xref>; <xref ref-type="bibr" rid="bib48">Maciolek et al., 2014</xref>; <xref ref-type="bibr" rid="bib81">Wang and Solt, 2016</xref>). Different types of T cells are usually associated with distinct metabolic status and features. Unlike effector T cells, including Th1, Th2, and Th17, which ‘prefer’ FAS, iTreg cells ‘favor’ FAO (<xref ref-type="bibr" rid="bib48">Maciolek et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Michalek et al., 2011</xref>; <xref ref-type="bibr" rid="bib78">Wang et al., 2011</xref>). During iTreg differentiation, suppressing FAS could probably be advantageous to keep the differentiation process on the right track and prevent differentiating cells from rushing into unwanted pathways. Also, we found that downregulation of FAS reduced malonyl-CoA, the potent physiological inhibitor of CPT1, and this could facilitate the unleashing of CPT1 activity for FAO and thereby iTreg differentiation. Therefore, reprogramming in fatty acid metabolism, in particular, the switch from FAS to FAO, is vital for the efficient differentiation of iTreg cells.</p><p>Although the essential role of FAO and CPT1 in iTreg differentiation has been documented (<xref ref-type="bibr" rid="bib49">MacIver et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">Michalek et al., 2011</xref>; <xref ref-type="bibr" rid="bib59">Patel and Powell, 2017</xref>; <xref ref-type="bibr" rid="bib90">Zhang et al., 2017</xref>), a more recent investigation challenged this conclusion and proposed that CPT1 is dispensable for iTreg differentiation (<xref ref-type="bibr" rid="bib63">Raud et al., 2018</xref>). <xref ref-type="bibr" rid="bib63">Raud et al., 2018</xref> found that naive CD4<sup>+</sup> T cells isolated from mice with CPT1 deletion in T cells (TCPT1 mice) did not seem to have any defect in iTreg differentiation and proposed that the phenotypes induced by high-dose CPT1 inhibitor, etomoxir (&gt;100 μM), were due to the off-target effect. However, we found that siRNA-mediated <italic>Cpt1</italic> knockdown or low-dose etomoxir (5 μM), which inhibits CPT1 without introducing off-target effects, impaired iTreg differentiation in vitro (<xref ref-type="bibr" rid="bib31">Hao et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">O'Connor et al., 2018</xref>; <xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5B</xref>). Of note, TCPT1 mice reported in <xref ref-type="bibr" rid="bib63">Raud et al., 2018</xref> survived from the lack of CPT1. One thus can envision that various metabolic genes/regulators have to be re-adjusted to compensate for the loss of CPT1, and metabolic homeostasis needs to be re-established. As a consequence, the defect(s) associated with the loss of CPT1 would be gradually compensated or masked during mouse development. In contrast, blocking CPT1 function by a specific inhibitor or siRNA that mimics an acute disruption in FAO might be useful for minimizing long-term metabolic adaption and directly evaluating CPT1 function in iTreg differentiation. In addition, our in vitro functional assays showed that alterations in CPT1 activity induced by ACLY and/or CUL3 depletion failed to change the suppressive function of iTreg cells (<xref ref-type="fig" rid="fig4">Figure 4D,I</xref>, <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A–B</xref>). In a recent study, <xref ref-type="bibr" rid="bib66">Saravia et al., 2020</xref> also showed that the deletion of CPT1 in Foxp3<sup>+</sup> Treg cells did not influence cell proliferation or function (<xref ref-type="bibr" rid="bib66">Saravia et al., 2020</xref>). Together, these findings argue that CPT1 may be dispensable for the regulation and maintenance of iTreg function.</p><p>FAS is controlled by a series of enzymes, three of which are rate-limiting enzymes, namely ACLY, ACC, and FASN. During iTreg differentiation, only ACLY changed significantly. These observations suggest that, rather than ACC and FASN, ACLY is apt to function as a sensor for FAS to respond to TGFβ1 signal. ACLY is responsible for the conversion of citrate into acetyl-CoA and OAA. Its enzymatic activity and expression are tightly coupled with the level of citrate, which could block glycolysis by inhibiting phosphofructokinase (PFK) (<xref ref-type="bibr" rid="bib34">Iacobazzi and Infantino, 2014</xref>; <xref ref-type="bibr" rid="bib87">Zaidi et al., 2012</xref>). Notably, inhibition of glycolysis has a positive impact on iTreg differentiation (<xref ref-type="bibr" rid="bib70">Shi et al., 2011</xref>). Therefore, TGFβ1-induced downregulation of ACLY, which is probably accompanied by citrate accumulation, might also contribute to the repression of glycolysis for iTreg differentiation.</p><p>Because of the great potential as a target for pharmaceutical intervention against hyperlipidemia, hypercholesterolemia, obesity, and cancer, ACLY has attracted considerable amount of attention over the recent decade (<xref ref-type="bibr" rid="bib19">Feng et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Migita et al., 2008</xref>). A growing list of ACLY inhibitors, including bempedoic acid (BemA), SB204990, curcumin, cinnamon polyphenol, and hydroxycitric acid, is under extensive investigation. It is worth mentioning that BemA, a small molecule inhibiting liver-specific ACLY, has been tested in a phase-three clinical trial for the control and treatment of hypercholesterolemia (<xref ref-type="bibr" rid="bib19">Feng et al., 2020</xref>; <xref ref-type="bibr" rid="bib60">Pinkosky et al., 2016</xref>). Results in this work have shown that ACLY inhibition by SB204990 effectively alleviated colitis in mice, suggesting that this small-molecule inhibitor (SB204990) may have a promising role in the clinical treatment for IBD. Thus, future investigations systematically evaluating ACLY as a drugable target for IBD and other immune diseases are in need.</p><p>Functional characterization of CUL3-KLHL25-mediated ACLY ubiquitination pinpoints ACLY as a regulatory node integrating TGFβ1 signaling with iTreg differentiation and therefore brings insights into the modulation and maintenance of immune homeostasis. Moreover, ACLY inhibitors with pharmaceutical potentials are apparently of interest for immunotherapy of autoimmunity and unwanted inflammation and certainly require further investigations.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or <break/>resource</th><th>Designation</th><th>Source or <break/>reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Strain, strain background (<italic>Mus musculus</italic>)</td><td>C57BL/6J</td><td>Beijing HFK Bioscience</td><td/><td/></tr><tr><td>Strain, strain background (<italic>M. musculus</italic>)</td><td><italic>Cd4</italic><sup>Cre</sup></td><td><xref ref-type="bibr" rid="bib16">Dong et al., 2008</xref></td><td/><td/></tr><tr><td>Strain, strain background (<italic>M. musculus</italic>)</td><td><italic>Cul3<sup>fl/fl</sup></italic></td><td>The Jackson Laboratory</td><td>Stock #: 028349</td><td/></tr><tr><td>Strain, strain background (<italic>M. musculus</italic>)</td><td><italic>Cd4<sup>Cre</sup>Cul3<sup>fl/fl</sup></italic></td><td>This paper</td><td/><td/></tr><tr><td>Strain, strain background (<italic>M. musculus</italic>)</td><td><italic>Foxp3<sup>YFP-Cre</sup></italic></td><td>The Jackson Laboratory</td><td>Stock #: 016959</td><td/></tr><tr><td>Strain, strain background (<italic>M. musculus</italic>)</td><td>B6/<italic>Rag1<sup>-/-</sup></italic></td><td>Jiangsu Gempharmatech</td><td>Stock #: T011699</td><td/></tr><tr><td>Cell line (<italic>Homo sapiens</italic>)</td><td>HEK293T</td><td>ATCC</td><td>Cat. #: ACS-4500</td><td/></tr><tr><td>Biological sample (<italic>Homo sapiens</italic>)</td><td>Healthy adult peripheral blood</td><td>Jilin blood center</td><td/><td/></tr><tr><td>Antibody</td><td>Mouse anti-CD3/CD28 beads</td><td>Gibco</td><td>Cat. #: 11453D</td><td>T-cell activation (beads:cells, 1:1)</td></tr><tr><td>Antibody</td><td>Human anti-CD3/CD28 beads</td><td>Gibco</td><td>Cat. #: 11132D</td><td>T-cell activation (beads:cells, 1:1)</td></tr><tr><td>Antibody</td><td>Anti-mouse CD4-FITC</td><td>BD Biosciences</td><td>Cat. #: 553046 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_394582">AB_394582</ext-link></td><td>FCM (1:200)</td></tr><tr><td>Antibody</td><td>Anti-mouse CD25-PE</td><td>BD Biosciences</td><td>Cat. #: 561065 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10563211">AB_10563211</ext-link></td><td>FCM (1:200)</td></tr><tr><td>Antibody</td><td>Anti-mouse Foxp3- Alexa Fluor 647</td><td>BD Biosciences</td><td>Cat. #: 560401 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1645201">AB_1645201</ext-link></td><td>FCM (1:200)</td></tr><tr><td>Antibody</td><td>Anti-human CD4-FITC</td><td>Biolegend</td><td>Cat. #: 357406 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2562357">AB_2562357</ext-link></td><td>FCM (1:200)</td></tr><tr><td>Antibody</td><td>Anti-human CD25-PE</td><td>Biolegend</td><td>Cat. #: 302605 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_314275">AB_314275</ext-link></td><td>FCM (1:200)</td></tr><tr><td>Antibody</td><td>Anti-human Foxp3- Alexa Fluor 647</td><td>Biolegend</td><td>Cat. #: 320114 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_439754">AB_439754</ext-link></td><td>FCM (1:200)</td></tr><tr><td>Antibody</td><td>Anti-mouse CTLA4-PE-Cy7</td><td>Biolegend</td><td>Cat. #: 106311 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10901170">AB_10901170</ext-link></td><td>FCM (1:200)</td></tr><tr><td>Antibody</td><td>Anti-mouse ICOS-PE-Cy7</td><td>Biolegend</td><td>Cat. #: 117421 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2860636">AB_2860636</ext-link></td><td>FCM (1:200)</td></tr><tr><td>Antibody</td><td>Anti-mouse TIGIT-PE-Cy7</td><td>Biolegend</td><td>Cat. #: 142107 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2565648">AB_2565648</ext-link></td><td>FCM (1:200)</td></tr><tr><td>Antibody</td><td>Anti-mouse IL-10-PE-Cy7</td><td>Biolegend</td><td>Cat. #: 505025 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_11149682">AB_11149682</ext-link></td><td>FCM (1:200)</td></tr><tr><td>Antibody</td><td>Anti-ACLY</td><td>Abcam</td><td>Cat. #: Ab40793 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_722533">AB_722533</ext-link></td><td>IP (1:100) <break/>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Anti-eGFP</td><td>Proteintech</td><td>Cat. #: 66002–1-Ig RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_11182611">AB_11182611</ext-link></td><td>IP (1:100) <break/>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Anti-Actin</td><td>Proteintech</td><td>Cat. #: 66009–1-Ig RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2687938">AB_2687938</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Anti-CUL3</td><td>Santa Cruz</td><td>Cat. #: sc-166110 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2245478">AB_2245478</ext-link></td><td>IP (1:50) <break/>WB (1:200)</td></tr><tr><td>Antibody</td><td>Anti-KLHL25</td><td>Santa Cruz</td><td>Cat. #: sc-100774 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1124139">AB_1124139</ext-link></td><td>IP (1:50) <break/>WB (1:200)</td></tr><tr><td>Antibody</td><td>Anti-UBR4</td><td>Abcam</td><td>Cat. #: Ab86738 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1952666">AB_1952666</ext-link></td><td>IP (1:100) <break/>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Anti-USP13</td><td>Santa Cruz</td><td>Cat. #: sc-514416</td><td>IP (1:50) <break/>WB (1:200)</td></tr><tr><td>Antibody</td><td>Anti-Ubiquitin</td><td>Abcam</td><td>Cat. #: ab7780 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_306069">AB_306069</ext-link></td><td>IP (1:100) <break/>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Anti-Lamin b1</td><td>CST</td><td>Cat. #: 12586</td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Anti-β-Tubulin</td><td>Sigma</td><td>Cat. #: T0198 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2210695">AB_2210695</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Anti-ATP5A1</td><td>Bimake</td><td>Cat. #: A5288</td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Anti-Pan-acetylation</td><td>CST</td><td>Cat. #: 9441 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331805">AB_331805</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Goat anti-Rabbit</td><td>Signalway Antibody</td><td>Cat. #: L3012-2</td><td>WB (1:10,000)</td></tr><tr><td>Antibody</td><td>Goat anti-Mouse</td><td>Signalway Antibody</td><td>Cat. #: L3032-2</td><td>WB (1:10,000)</td></tr><tr><td>Commercial assay or kit</td><td>Mouse CD4<sup>+</sup>Naïve T Cell isolation kit</td><td>Biolegend</td><td>Cat. #: 480040</td><td/></tr><tr><td>Commercial assay or kit</td><td>Human CD4<sup>+</sup>Naïve T Cell isolation kit</td><td>Biolegend</td><td>Cat. #: 480042</td><td/></tr><tr><td>Commercial assay or kit</td><td>Mouse T cell nucleofection kit</td><td>Lonza</td><td>Cat. #: VPA1006</td><td/></tr><tr><td>Commercial assay or kit</td><td>Mouse mevalonate ELISA kit</td><td>Sino Best Biological Technology</td><td>Cat. #: YX-132201M</td><td/></tr><tr><td>Commercial assay or kit</td><td>Mouse MCPT1 ELISA kit</td><td>Sino Best Biological Technology</td><td>Cat. #: YX-130316M</td><td/></tr><tr><td>Commercial assay or kit</td><td>Mouse OVA-specific IgE ELISA kit</td><td>Sino Best Biological Technology</td><td>Cat. #: YX-152201M</td><td/></tr><tr><td>Commercial assay or kit</td><td>Mouse mevalonate-5-pyrophosphate ELISA kit</td><td>Shanghai Ruifan Biological Technology</td><td>Cat. #: RF8872</td><td/></tr><tr><td>Commercial assay or kit</td><td>Mouse HMG-CoA ELISA kit</td><td>Shanghai Ruifan Biological Technology</td><td>Cat. #: RF8726</td><td/></tr><tr><td>Commercial assay or kit</td><td>Mitochondrial isolation kit</td><td>Beyotime Biotechnology</td><td>Cat. #: C3601</td><td/></tr><tr><td>Commercial assay or kit</td><td>Cell Nuclear/Cytoplasm Protein Isolation Kit</td><td>Beyotime Biotechnology</td><td>Cat. #: P0028</td><td/></tr><tr><td>Commercial assay or kit</td><td>ACLY activity assay kit</td><td>Suzhou comin Biotechnology</td><td>Cat. #: ACL-1-Y</td><td/></tr><tr><td>Commercial assay or kit</td><td>ACC activity assay kit</td><td>Suzhou comin Biotechnology</td><td>Cat. #: ACC-1-Y</td><td/></tr><tr><td>Commercial assay or kit</td><td>FASN activity assay kit</td><td>Suzhou comin Biotechnology</td><td>Cat. #: FASN-1-Y</td><td/></tr><tr><td>Commercial assay or kit</td><td>CPT1 activity assay kit</td><td>Suzhou comin Biotechnology</td><td>Cat. #: CPT1-1-Y</td><td/></tr><tr><td>Commercial assay or kit</td><td>Acetyl-CoA Fluorometric Assay kit</td><td>BioVision</td><td>Cat. #: K317-100</td><td/></tr><tr><td>Commercial assay or kit</td><td>OAA assay kit</td><td>Sigma</td><td>Cat. #: MAK070</td><td/></tr><tr><td>Commercial assay or kit</td><td>Transcriptional factor buffer set</td><td>BD</td><td>Cat. #: 562574</td><td/></tr><tr><td>Commercial assay or kit</td><td>CFSE</td><td>Biolegend</td><td>Cat. #: 423801</td><td>1 μM</td></tr><tr><td>Commercial assay or kit</td><td>CellTrace Violet</td><td>Thermo Fisher</td><td>Cat. #: C34557</td><td>1 μM</td></tr><tr><td>Commercial assay or kit</td><td>Mito Stress Test kits</td><td>Agilent</td><td>Cat. #: 103010–100</td><td/></tr><tr><td>Commercial assay or kit</td><td>Seahorse XF Palmitate-BSA FAO substrate</td><td>Agilent</td><td>Cat. #: 102720–100</td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pWPXLD-mACLY (plasmid)</td><td>This paper</td><td/><td/></tr><tr><td>Recombinant DNA reagent</td><td>pWPXLD-mACLY<sup>3KR(K530/536/544)</sup>(plasmid)</td><td>This paper</td><td/><td/></tr><tr><td>Recombinant DNA reagent</td><td>pWPXLD-hACLY (plasmid)</td><td>This paper</td><td/><td/></tr><tr><td>Recombinant DNA reagent</td><td>pWPXLD-hACLY<sup>3KR(K540/546/554)</sup>(plasmid)</td><td>This paper</td><td/><td/></tr><tr><td>Peptide, recombinant protein</td><td>Recombinant mouse IL-2</td><td>Peprotech</td><td>Cat. #: 212–12</td><td>7.5 ng/ml</td></tr><tr><td>Peptide, recombinant protein</td><td>Recombinant human IL-2</td><td>Gibco</td><td>Cat. #: PHC0026</td><td>7.5 ng/ml</td></tr><tr><td>Peptide, recombinant protein</td><td>Recombinant human TGFβ1</td><td>Peprotech</td><td>Cat. #: 100-21-10</td><td>0.5 or 2 ng/ml</td></tr><tr><td>Chemical compound, drug</td><td>SB204990</td><td>Tocris Bioscience</td><td>Cat. #: 154566-12-8</td><td>100 μM</td></tr><tr><td>Chemical compound, drug</td><td>MG132</td><td>Selleck</td><td>Cat. #: S2619</td><td>10, 20, or 40 μM</td></tr><tr><td>Chemical compound, drug</td><td>CHX</td><td>Tocris Bioscience</td><td>Cat. #: 0970</td><td>10 μg/ml</td></tr><tr><td>Chemical compound, drug</td><td>Leupeptin</td><td>Selleck</td><td>Cat. #: S7380</td><td>0.4 or 0.8 mM</td></tr><tr><td>Chemical compound, drug</td><td>Dextran sulfate sodium (36,000–50,000)</td><td>MP Biomedicals</td><td>Cat. #: 0216011080</td><td>2%</td></tr><tr><td>Chemical compound, drug</td><td>PF05175157</td><td>TOCRIS</td><td>Cat. #: 5709</td><td>5 μM</td></tr><tr><td>Chemical compound, drug</td><td>Cerulenin</td><td>Biovision</td><td>Cat. #: 1579–5</td><td>4 μM</td></tr><tr><td>Software, algorithm</td><td>FlowJo 10.1</td><td>FlowJo LLC</td><td><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/">https://www.flowjo.com/</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td>GraphPad Prism 6</td><td>GraphPad Software</td><td><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com">https://www.graphpad.com</ext-link></td><td/></tr><tr><td>Other</td><td>RPMI 1640</td><td>Sigma-Aldrich</td><td>Cat. #: R66504</td><td/></tr><tr><td>Other</td><td>Fetal bovine serum</td><td>Biological Industries</td><td>Cat. #: 04-001-01</td><td/></tr><tr><td>Other</td><td>XF Base Medium</td><td>Agilent</td><td>Cat. #: 103193–100</td><td/></tr><tr><td>Other</td><td>OVA</td><td>Sigma-Aldrich</td><td>Cat. #: A5503</td><td/></tr><tr><td>Other</td><td>Polybrene</td><td>Solarbio</td><td>Cat. #: H8761</td><td>8 μg/ml</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p>C57BL/6J (B6) and B6/<italic>Rag1<sup>-/-</sup></italic> mice were purchased from Beijing HFK Bioscience Co, Ltd, China, and Jiangsu Gempharmatech Co, Ltd, China, respectively. <italic>Cul3<sup>fl/fl</sup></italic> mice were generously sponsored by Jeffrey D Singer (Department of Biology, Portland State University, Portland, OR, USA.). <italic>Cd4<sup>Cre</sup></italic> transgenic mice were generously provided by Zichun Hua (The State Key Laboratory of Pharmaceutical Biotechnology, Department of Biochemistry, College of Life Sciences, Nanjing University, Nanjing). <italic>Cd4<sup>Cre</sup></italic> and <italic>Cul3<sup>fl/fl</sup></italic> mice were crossed to generate mice specifically lacking CUL3 in their CD4<sup>+</sup> T cells. Polymerase chain reaction (PCR) primers used for amplifying <italic>Cd4<sup>Cre</sup></italic> transgene and <italic>Cul3<sup>fl/fl</sup></italic> mutant are shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. <italic>Foxp3<sup>YFP-Cre</sup></italic> mice were purchased from the Jackson laboratory.</p><p>Mice were bred and cohoused, four to six mice per cage, in a specific pathogen-free facility with a standard 12-hr alternate light/dark cycle at an ambient temperature of 22 ± 2°C and 30–70% humidity at the Animal Research Center of Northeast Normal University (Changchun, China). Health status of mice was determined via daily observation by technicians supported by veterinary care. All mouse experiments were conducted in accordance with the protocols for animal use, treatment, and euthanasia approved by the local ethics committee (reference number: AP2019085, the institutional animal care and use committee (IACUC) of the Northeast Normal University).</p></sec><sec id="s4-2"><title>Induction of mouse iTreg in vitro</title><p>Naive CD4<sup>+</sup> T cells were isolated from the spleen of female mice at the age of 6–8 weeks with MojoSort Mouse CD4<sup>+</sup> Naïve T Cell Isolation Kit (Biolegend) according to the manufacturer’s instructions. For Th0 induction, 2 to 3 × 10<sup>5</sup> naive CD4<sup>+</sup> T cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS) (Biological Industries), penicillin-streptomycin (500 U; PAN biotech), and β-mercaptoethanol (50 μM; Sigma-Aldrich) and stimulated with Dynabeads Mouse T-Activator CD3/CD28 (Gibco) at a cell:bead ratio of 1:1 in the presence of rmIL-2 (200 U/ml; Peprotech) (<xref ref-type="bibr" rid="bib80">Wang et al., 2019</xref>). To obtain iTreg cells, rhTGFβ1 (2 or 0.5 ng/ml; Peprotech) was simultaneously added along with the reagents used for inducing Th0 cells. ACLY inhibitor: SB204990 (Tocris Bioscience), ACC inhibitor: PF05175157 (Tocris Bioscience), FASN inhibitor: cerulenin (Biovision), protein synthesis inhibitor: CHX (Tocris Bioscience), proteasome inhibitor: MG132 (Selleck), lysosome inhibitor: leupeptin (Selleck).</p></sec><sec id="s4-3"><title>Induction of human iTreg in vitro</title><p>Human peripheral blood samples were obtained from Jilin Blood Center (Changchun, China). All work with human blood samples was approved by the local ethics committee (reference number: AP2019085, the ethical committee of the Northeast Normal University), and informed consent was obtained from all subjects. After Ficoll (GENVIEW) gradient, naive CD4<sup>+</sup> T cells were isolated with MojoSort human CD4<sup>+</sup> Naïve T Cell Isolation Kit (Biolegend) according to the manufacturer’s instructions (<xref ref-type="bibr" rid="bib26">Ghosh et al., 2016</xref>). For Th0 induction, 2 to 3 × 10<sup>5</sup> naive CD4<sup>+</sup> T cells were cultured in RPMI 1640 medium (Sigma) supplemented with 10% FBS (Biological Industries), penicillin-streptomycin (500 U; PAN biotech), and β-mercaptoethanol (50 μM; Sigma-Aldrich) and stimulated with Dynabeads human T-Activator CD3/CD28 (Gibco) at a cell:bead ratio of 1:1 in the presence of rhIL-2 (200 U/ml; Gibco). To obtain iTreg cells, rhTGFβ1 (2 or 0.5 ng/ml; Peprotech) was simultaneously added along with the reagents used for inducing Th0 cells.</p></sec><sec id="s4-4"><title>Flow cytometry analysis</title><p>Cells were collected in phosphate-buffered saline (PBS) containing 1% FBS (v/v) and fixed/permeabilized using the Transcription Factor Buffer Set (BD Biosciences) according to the manufacturer’s instructions. For mouse iTreg analysis, selected protein markers were stained with fluorescein isothiocyanate (FITC) rat anti-mouse CD4, phycoerythrin (PE) rat anti-mouse CD25, and Alexa Fluor 647 rat anti-mouse Foxp3 monoclonal antibodies (BD Biosciences). For human iTreg analysis, protein markers were stained with FITC rat anti-human CD4, PE mouse anti-human CD25, and Alexa Fluor 647 mouse anti-human Foxp3 monoclonal antibodies (Biolegend).</p></sec><sec id="s4-5"><title>Quantitative real-time PCR</title><p>Total RNA was isolated using the TRIzol reagent (Invitrogen). Complementary DNA (cDNA) was synthesized with the PrimeScript RT reagent Kit plus gDNA Eraser (Takara) according to the manufacturer’s instructions. Real-time PCR was performed on the QuantStudio 3 Real-Time PCR Instrument (Applied Biosystems) with a TB Green Premix Ex Taq (Tli RNaseH Plus) reagent (Takara). The mRNA expression of genes was normalized to the expression of β-actin gene. Data were analyzed using the comparative cycling threshold method. Quantitative PCR primers are shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-6"><title>siRNA transfection</title><p>All siRNA transfections were performed with Mouse T-cell nucleofection kit (Lonza) according to the instructions using X-001 progress as described previously (<xref ref-type="bibr" rid="bib51">Mantei et al., 2008</xref>). Cells were transiently transfected with siRNAs (siRNAs against <italic>Acly</italic>, <italic>Cul3,</italic> and <italic>Klhl25</italic> were commercially synthesized; Shanghai GenePharma) at a final concentration of 20 nM and rested in RPMI-1640 (with 10% FBS) for 4–5 hr before incubation under different conditions (Th0 or iTreg) for a desired period of time. siRNA sequences are shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-7"><title>Plasmid construction</title><p>DNA sequences coding mouse <italic>Acly</italic> gene (NCBI Accession No. NM_001199296.1) from mouse CD4<sup>+</sup> T cells and human <italic>Acly</italic> gene (NCBI Accession No. NM_001096.3) from human CD4<sup>+</sup> T cells were amplified by PCR and subsequently cloned into pWPXLd vector (containing green fluorescent protein (GFP) sequence) to construct pWPXLd-mACLY and pWPXLd-hACLY, respectively. K530, K536, and K544 mutations in mACLY and K540, K546, and K554 in hACLY were introduced by whole-plasmid PCR followed by DpnI digestion to obtain pWPXLd-mACLY<sup>3KR (K530/K536/K544)</sup> and pWPXLd-hACLY<sup>3KR (K540/K546/K554)</sup>.</p></sec><sec id="s4-8"><title>Lentivirus transduction of CD4<sup>+</sup> T cells</title><p>HEK293T cells (without mycoplasma contamination) were grown in 10-cm cell-culture dishes to 70% confluence and were transfected with a three-plasmid system (pWPXLd-ACLY, PAX, PMD). The supernatant was harvested at 48, 72, and 96 hr after transfection and was concentrated 100-fold in an ultracentrifuge. Aliquots were stored at −80°C. Naive CD4<sup>+</sup> T cells were cultured under Th0-inducing condition as described above for 16–24 hr and were spin infected for two rounds with lentivirus supernatants (ACLY<sup>WT</sup>, ACLY<sup>3KR</sup>, or Empty) in the presence of 8 μg/ml polybrene (Solarbio) at 1000 ×<italic>g</italic>, 90 min, at 32°C as described previously (<xref ref-type="bibr" rid="bib44">Lin et al., 2019</xref>; <xref ref-type="bibr" rid="bib74">Sun et al., 2015</xref>). After 24 hr of infection, supernatants were removed and cells were selectively cultured under either Th0- or iTreg-inducing condition for a desired period of time.</p></sec><sec id="s4-9"><title>Assessment of metabolic molecules</title><p>For acetyl-CoA and OAA detection, cytosolic fractions from Th0 or iTreg cells were separated using Cell Mitochondria Isolation Kit (Beyotime). In brief, cells were washed with cold PBS, followed by homogenation for 20 s, and then centrifuged twice (first round, 600 ×<italic>g</italic> for 5 min; second round, 11,000 <italic>×g</italic> for 5 min). Supernatants that represent cytosolic fractions without nuclei and mitochondria were confirmed by western blotting (WB) and deproteinized with a 10-kD spin filter by centrifuge for effluent preparation. Nuclear fraction was separated using Cell Nuclear/Cytoplasm Protein Isolation Kit (Beyotime) and also confirmed by WB. Cytosolic/nuclear acetyl-CoA and cytosolic OAA were assessed using PicoProbe acetyl-CoA fluorometric assay kit (Biovision) and OAA assay kit (Sigma), respectively, according to the manufacturer’s protocol. For the analysis of malonyl-CoA, cells were cultured under iTreg-polarization condition for 24 hr and lysed with ice-cold 5% sulfosalicylic acid (Sigma-Aldrich) containing 50 μM dithioerythritol (DTE) (Sigma-Aldrich). After 600 ×<italic>g</italic> centrifugation for 10 min at 4°C, the supernatants were collected for the detection of malonyl-CoA by high-performance liquid chromatography (HPLC). For the detection of HMG-CoA, mevalonate, and mevalonate-5-pyrophosphate, cells were homogenized in PBS and the supernatants were collected for detection of HMG-CoA, mevalonate, and mevalonate-5-pyrophosphate using HMG-CoA enzyme-linked immunosorbent assay (ELISA) kit (Shanghai Ruifan Biological Technology), Mevalonate ELISA kit (Sino Best Biological Technology), and Mevalonate-5-pyrophosphate ELISA kit (Shanghai Ruifan Biological Technology) according to the manufacturers’ instructions. Equal amount of cells was used for different groups in the same assay.</p></sec><sec id="s4-10"><title>Extracellular flux analysis</title><p>For the FAO-associated oxygen consumption rate (OCR) assay by Seahorse XFp Analyzer (Agilent), Palmitate-BSA reagent (Agilent) and Mito Stress Test Kits (Agilent) were used according to the manufacturers’ instructions with minor modifications. In brief, cells were collected and adhered to poly-D-lysine-coated XFp plates (4 to 6 × 10<sup>5</sup> cells/well) via centrifugation in serum-free XF Base Medium (Agilent). For evaluation of palmitate oxidation, cells were cultured with XF Base Medium (Agilent) in a non-CO<sub>2</sub> incubator for 15–20 min at 37°C. Subsequently, the XF Palmitate-BSA FAO Substrates (Agilent) palmitate-BSA (167 μM palmitate conjugated with 28 μM BSA) and 0.5 mM L-carnitine (Sigma Aldrich) were added to the medium for the assessment of OCR. Immediately, XF Cell Mito Stress Test was performed in a Seahorse XFp Analyzer (Agilent) by sequentially adding several modulators of mitochondrial function, including 1 mM oligomycin (Oligo) (Agilent), 1.5 mM fluorocarbonyl cyanide phenylhydrazone (FCCP) (Agilent), and 100 nM rotenone plus 1 mM antimycin A (Rot/Ant A) (Agilent). Data were analyzed with Wave software version 2.3.0 (Agilent) and proper statistical methods using GraphPad Prism version 6 (GraphPad Software).</p></sec><sec id="s4-11"><title><sup>13</sup>C-tracing assessment</title><p>Cell samples cultured in a medium containing [U-<sup>13</sup>C] glucose (11 mM) were mixed with 10 μl formate and 800 μl chloroform, and processed by four cycles of 1 min ultra-sonication and 1 min interval in ice-water bath followed by standing for 30 min at room temperature prior to centrifugation at 3000 <italic>×g</italic> for 15 min. All chloroform was transferred to a new glass vial and mixed with 500 μl 75% ethanol (containing 0.5 M KOH) prior to incubation at 80°C for 60 min. Then, the mixture was added with 600 μl of hexane and vortexed for 1 min and made to stand for 30 min. After centrifugation at 3000 ×<italic>g</italic> for 15 min, all hexane layers were evaporated to dryness. The dry residue deposit was mixed with 10 μl 1-hydroxybenzotriazole (HoBt) (in dimethyl sulfoxide [DMSO]), 20 μl cholamine (in DMSO with 200 mM triethylamine [TEA]), and 10 μl O-(7-azabenzotriazol-1yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) (in DMSO) followed by incubating for 5 min at room temperature. 60 μl acetonitrile was added, followed by centrifuging at 3000 <italic>×g</italic> for 15 min at 4°C prior to UHPLC-HRMS analysis.</p><p>The ultra-high performance liquid chromatography-tandem mass-spectrometry (UHPLC-MS/MS) analysis was performed on an Agilent 1290 Infinity II UHPLC system coupled to a 6470A Triple Quadrupole mass spectrometre (Santa Clara, CA, United States). Samples were injected onto a Waters UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm) at a flow rate of 0.3 ml/min. The mobile phase consisted of water (phase A) and acetonitrile (phase B), both with 0.1% formate. The chromatographic separation was conducted by a gradient elution program as follows: 0 min, 10% B; 4 min, 40% B; 8 min, 45% B; 11 min, 50% B; 14 min, 70% B; 15 min, 90% B; 15.5 min, 100% B; 18 min, 100% B; 18.1 min, 10% B; 20 min, 10% B. The column temperature was 40°C. The raw data were processed by Agilent MassHunter Workstation Software (version B.08.00) by using the default parameters and assisting manual inspection to ensure the qualitative and quantitative accuracies of each compound. The peak areas of target compounds were integrated and the output was run for IsoCorrection analysis.</p></sec><sec id="s4-12"><title>Assessment of metabolic enzyme activities</title><p>Cells were lysed by ultrasonic treatment in extracting buffer from the kits. Supernatants were collected and used for the analyses of enzymatic activities. ACC Activity Assay Kit (Suzhou Comin), ACLY Activity Assay Kit (Suzhou Comin), FASN Activity Assay Kit (Suzhou Comin), and CPT1 Activity Assay Kit (Suzhou Comin) were used according to the manufacturers’ instructions.</p></sec><sec id="s4-13"><title>Immunoprecipitation and western blotting</title><p>Cells were lysed in cold western blot-immunoprecipitation (WB-IP) lysis buffer (Beyotime) for 30 min and centrifuged (at 4°C, 5 min, at 14,000 <italic>×g</italic>) to remove cell debris. The supernatant was collected as a whole-cell lysate. ACLY, ubiquitin (Ub), and CUL3 were immunoprecipitated from the whole-cell lysates using anti-ACLY (Abcam), anti-ubiquitin (Abcam), and anti-CUL3 (Santa Cruz Biotechnology) antibodies coupling to Protein A/G PLUS Agarose Beads (Santa Cruz Biotechnology) overnight at 4°C. Nonspecific rabbit or mouse IgG antibody was used as a negative control. Immunoprecipitated proteins were mixed with 1× loading buffer and boiled at 100°C for 10 min followed by WB. For WB, protein samples were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and then proteins were transferred to polyvinylidene fluoride membranes (Millipore). The membranes were blocked with 5% nonfat milk for 1 hr at room temperature before incubation with primary antibodies overnight at 4°C. Mouse- or rabbit-conjugated horseradish peroxidase (HRP) secondary antibodies were added to the membranes for 50 min at room temperature, followed by washing three times with 1× Tris-buffered saline with Tween 20 (TBST), and visualized using Chemiluminescent HRP Substrate (Millipore) on Chemiluminescence Image System (Tanon Science and Technology Co, Ltd). The antibodies for WB are shown in Key Resources Table.</p></sec><sec id="s4-14"><title>In vitro iTreg suppression assay</title><p>Naive CD4<sup>+</sup> T cells from WT or <italic>Cd4<sup>Cre</sup>Cul3<sup>fl/fl</sup></italic> mice were transfected with <italic>Acly</italic>-specific or scramble siRNA and cultured under Th0- or iTreg-polarization condition for 72 hr to obtain Th0 (WT), iTreg (WT), iTreg (<italic>Cul3<sup>-/-</sup></italic>), and iTreg (<italic>Cul3<sup>-/-</sup></italic>+si<italic>Acly</italic>) cells. Meanwhile, 2 × 10<sup>5</sup> freshly isolated naive CD4<sup>+</sup> T cells from WT mice pulse-labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE) (Biolegend) at 0.5 μM for 20 min were co-cultured with different groups of iTreg cells at a ratio of 1:1 in the presence of Dynabeads Mouse T-Activator CD3/CD28 for 72 hr as described previously (<xref ref-type="bibr" rid="bib13">De Rosa et al., 2015</xref>). The flow cytometry was used for the assessment of CFSE dilution, which indicates the suppressive function of iTreg cells in vitro.</p><p>Naive CD4<sup>+</sup> T cells from <italic>Foxp3<sup>YFP-Cre</sup></italic> mice were transfected with siRNAs against <italic>Acly</italic> and (or) <italic>Cul3</italic> and cultured under Th0- or iTreg-polarization condition for 72 hr followed by sorting yellow fluorescent protein (YFP)-positive cells to obtain Th0, YFP-iTreg, YFP-iTreg (si<italic>Cul3</italic>), and YFP-iTreg (si<italic>Cul3</italic>+si<italic>Acly</italic>) cells. Meanwhile, 2 × 10<sup>5</sup> freshly isolated naive CD4<sup>+</sup> T cells from WT mice pulse-labeled with CellTrace Violet (CTV) (Thermo Fisher) at 1 μM for 20 min were co-cultured with different groups of iTreg cells at a ratio of 1:1 in the presence of Dynabeads Mouse T-Activator CD3/CD28 for 72 hr as described previously. The flow cytometry was used for the assessment of CTV dilution (<xref ref-type="bibr" rid="bib36">Johnson et al., 2018</xref>), which indicates the suppressive function of iTreg cells in vitro.</p></sec><sec id="s4-15"><title>Mouse model of colitis</title><p>T-cell transfer colitis based on adoptive transfer of naive CD4<sup>+</sup> T cells into <italic>Rag1<sup>-/-</sup></italic> mice is widely used for studying chronic intestinal inflammation (<xref ref-type="bibr" rid="bib22">Furusawa et al., 2013</xref>). As described previously, 5 × 10<sup>5</sup> freshly isolated naive CD4<sup>+</sup> T cells were administrated into <italic>Rag1<sup>-/-</sup></italic> mice by intraperitoneal injection to induce colitis. Concomitant injection of 5 × 10<sup>5</sup> Th0 (WT), iTreg (WT), iTreg (<italic>Cul3<sup>-/-</sup></italic>), or iTreg (<italic>Cul3<sup>-/-</sup></italic>+si<italic>Acly</italic>) cells was conducted for the evaluation of CUL3 and ACLY function. Meanwhile, <italic>Rag1<sup>-/-</sup></italic> mice of blank control group were administrated with PBS. Moreover, the function of ACLY in acute colitis was also assessed in DSS-induced colitis model. DSS (MP Biomedicals) dissolved in drinking water (2%, w/v) was given ad libitum to 6- to 8-week-old female C57BL/6J mice for 7 days followed by water for 3 days (<xref ref-type="bibr" rid="bib83">Wirtz et al., 2017</xref>; <xref ref-type="bibr" rid="bib82">Wirtz et al., 2007</xref>). Mice supplied with regular drinking water were included as a negative control. ACLY inhibitor, SB204990 (37.5 mg/kg/d) (Tocris Bioscience), was administrated orally every 2 days before the assessment of colitis.</p></sec><sec id="s4-16"><title>Evaluation of colitis in mice</title><p>To assess the severity of colitis, DAI was weekly (T-cell transfer colitis) or daily (DSS-induced colitis) recorded by scoring the body weight loss, stool consistency, and blood in the stool as described in the literature (<xref ref-type="bibr" rid="bib22">Furusawa et al., 2013</xref>; <xref ref-type="bibr" rid="bib83">Wirtz et al., 2017</xref>; <xref ref-type="bibr" rid="bib82">Wirtz et al., 2007</xref>). 7 weeks later (T-cell transfer colitis) or 10 days later (DSS-induced colitis), mice were euthanized for the examination of histopathological changes in colon tissues. Entire colons were removed and colon length was determined. Following cleaning with saline and fixation with formalin, colon samples were embedded in paraffin. Sections (3 μm) were stained with hematoxylin and eosin (H and E) and slides were blindly analyzed for intestinal inflammation according to the previous description (<xref ref-type="bibr" rid="bib83">Wirtz et al., 2017</xref>; <xref ref-type="bibr" rid="bib82">Wirtz et al., 2007</xref>). In addition, for DSS-induced colitis, the mononuclear cells from MLNs and the cLP were prepared as described previously (<xref ref-type="bibr" rid="bib2">Atarashi et al., 2011</xref>) for the analysis of Treg cells by flow cytometry.</p></sec><sec id="s4-17"><title>Induction of allergic diarrhea</title><p>Mice were sensitized with 50 μg of OVA (Sigma Aldrich) and 1 mg of alum (Thermo) in sterile saline by interperitoneal (ip) injection. From day 14 on, mice were challenged by oral gavage with 50 mg of OVA in saline three times per week for 3 weeks as described. Mice showing profuse liquid stool within 60 min after oral OVA challenge were recorded as diarrhea-positive. Th0 and iTreg cells under various conditions were adoptively transferred into mice, respectively, by tail vein injection (iv) after the first and forth challenge. 2 hr after the last oral administration, mice were sacrificed and blood samples and intestinal tissues were collected for detection of OVA-specific IgE and MCPT1 in serum by ELISA and eosnophil infiltration by H and E staining.</p></sec><sec id="s4-18"><title>Data analysis and statistics</title><p>All experiments were done at least three times independently. Statistical analysis was performed using GraphPad Prism version 6 (GraphPad Software). Data are displayed as mean ± standard (SD). The p-values were calculated from Student’s unpaired t-test when comparing within two groups. One-way or two-way analysis of variance (ANOVA) was performed in the indicated figures when more than two groups were compared. p-values &lt;0.05 were considered significant. p-values were indicated on graphs as *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001; ns, nonsignificant.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Jeffrey D Singer (Department of Biology, Portland State University, Portland, OR, USA) and Zichun Hua (The State Key Laboratory of Pharmaceutical Biotechnology, Department of Biochemistry, College of Life Sciences, Nanjing University, Nanjing) for generously sponsoring the <italic>Cul3<sup>fl/fl</sup></italic> and <italic>Cd4<sup>Cre</sup></italic> mice, respectively. We also thank Weiwei Yang (Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, China) for critical comments. This work was supported by grants from the National Natural Science Foundation of China (32070896 and 31870896) and the Fundamental Research Funds for the Central Universities (2412019FZ028).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Software, Formal analysis, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Visualization, Methodology</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Visualization, Methodology</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con7"><p>Resources</p></fn><fn fn-type="con" id="con8"><p>Data curation</p></fn><fn fn-type="con" id="con9"><p>Software, Methodology</p></fn><fn fn-type="con" id="con10"><p>Data curation</p></fn><fn fn-type="con" id="con11"><p>Formal analysis</p></fn><fn fn-type="con" id="con12"><p>Formal analysis</p></fn><fn fn-type="con" id="con13"><p>Data curation</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Resources, Formal analysis</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Supervision, Funding acquisition, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Supervision, Funding acquisition, Validation, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: All work with human blood samples was approved by the local ethics committee (Reference number: AP2019085, the ethical committee of the Northeast Normal University), and informed consent was obtained from all subjects.</p></fn><fn fn-type="other"><p>Animal experimentation: All mouse experiments were conducted in accordance with the protocols for animal use, treatment, and euthanasia approved by the institutional animal care and use committee (IACUC) of Northeast Normal University (Reference number: AP2019085). The number of experimental mice used for research purposes is reduced as far as possible while still allowing the scientific purpose of the research to be achieved.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Original data and blots supporting main figures and figure supplements.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-62394-data1-v1.zip"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>List of oligonucleotides.</title><p>Primers for PCR and quantitative PCR, and sequences of siRNAs are included.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-62394-supp1-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-62394-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 1-6.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agbor</surname> <given-names>LN</given-names></name><name><surname>Nair</surname> <given-names>AR</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Lu</surname> <given-names>K-T</given-names></name><name><surname>Davis</surname> <given-names>DR</given-names></name><name><surname>Keen</surname> <given-names>HL</given-names></name><name><surname>Quelle</surname> <given-names>FW</given-names></name><name><surname>McCormick</surname> <given-names>JA</given-names></name><name><surname>Singer</surname> <given-names>JD</given-names></name><name><surname>Sigmund</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Conditional deletion of smooth muscle Cullin-3 causes severe progressive hypertension</article-title><source>JCI Insight</source><volume>4</volume><fpage>577</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1172/jci.insight.129793</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atarashi</surname> <given-names>K</given-names></name><name><surname>Tanoue</surname> <given-names>T</given-names></name><name><surname>Shima</surname> <given-names>T</given-names></name><name><surname>Imaoka</surname> <given-names>A</given-names></name><name><surname>Kuwahara</surname> <given-names>T</given-names></name><name><surname>Momose</surname> <given-names>Y</given-names></name><name><surname>Cheng</surname> <given-names>G</given-names></name><name><surname>Yamasaki</surname> <given-names>S</given-names></name><name><surname>Saito</surname> <given-names>T</given-names></name><name><surname>Ohba</surname> <given-names>Y</given-names></name><name><surname>Taniguchi</surname> <given-names>T</given-names></name><name><surname>Takeda</surname> <given-names>K</given-names></name><name><surname>Hori</surname> <given-names>S</given-names></name><name><surname>Ivanov</surname> <given-names>II</given-names></name><name><surname>Umesaki</surname> <given-names>Y</given-names></name><name><surname>Itoh</surname> <given-names>K</given-names></name><name><surname>Honda</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Induction of colonic regulatory T cells by indigenous Clostridium species</article-title><source>Science</source><volume>331</volume><fpage>337</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1126/science.1198469</pub-id><pub-id pub-id-type="pmid">21205640</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname> <given-names>CN</given-names></name><name><surname>Fried</surname> <given-names>M</given-names></name><name><surname>Krabshuis</surname> <given-names>JH</given-names></name><name><surname>Cohen</surname> <given-names>H</given-names></name><name><surname>Eliakim</surname> <given-names>R</given-names></name><name><surname>Fedail</surname> <given-names>S</given-names></name><name><surname>Gearry</surname> <given-names>R</given-names></name><name><surname>Goh</surname> <given-names>KL</given-names></name><name><surname>Hamid</surname> <given-names>S</given-names></name><name><surname>Khan</surname> <given-names>AG</given-names></name><name><surname>LeMair</surname> <given-names>AW</given-names></name><name><surname>Malfertheiner</surname></name><name><surname>Ouyang</surname> <given-names>Q</given-names></name><name><surname>Rey</surname> <given-names>JF</given-names></name><name><surname>Sood</surname> <given-names>A</given-names></name><name><surname>Steinwurz</surname> <given-names>F</given-names></name><name><surname>Thomsen</surname> <given-names>OO</given-names></name><name><surname>Thomson</surname> <given-names>A</given-names></name><name><surname>Watermeyer</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>World gastroenterology organization practice guidelines for the diagnosis and management of IBD in 2010</article-title><source>Inflammatory Bowel Diseases</source><volume>16</volume><fpage>112</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1002/ibd.21048</pub-id><pub-id pub-id-type="pmid">19653289</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berod</surname> <given-names>L</given-names></name><name><surname>Friedrich</surname> <given-names>C</given-names></name><name><surname>Nandan</surname> <given-names>A</given-names></name><name><surname>Freitag</surname> <given-names>J</given-names></name><name><surname>Hagemann</surname> <given-names>S</given-names></name><name><surname>Harmrolfs</surname> <given-names>K</given-names></name><name><surname>Sandouk</surname> <given-names>A</given-names></name><name><surname>Hesse</surname> <given-names>C</given-names></name><name><surname>Castro</surname> <given-names>CN</given-names></name><name><surname>Bähre</surname> <given-names>H</given-names></name><name><surname>Tschirner</surname> <given-names>SK</given-names></name><name><surname>Gorinski</surname> <given-names>N</given-names></name><name><surname>Gohmert</surname> <given-names>M</given-names></name><name><surname>Mayer</surname> <given-names>CT</given-names></name><name><surname>Huehn</surname> <given-names>J</given-names></name><name><surname>Ponimaskin</surname> <given-names>E</given-names></name><name><surname>Abraham</surname> <given-names>WR</given-names></name><name><surname>Müller</surname> <given-names>R</given-names></name><name><surname>Lochner</surname> <given-names>M</given-names></name><name><surname>Sparwasser</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells</article-title><source>Nature Medicine</source><volume>20</volume><fpage>1327</fpage><lpage>1333</lpage><pub-id pub-id-type="doi">10.1038/nm.3704</pub-id><pub-id pub-id-type="pmid">25282359</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Jin</surname> <given-names>W</given-names></name><name><surname>Hardegen</surname> <given-names>N</given-names></name><name><surname>Lei</surname> <given-names>KJ</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Marinos</surname> <given-names>N</given-names></name><name><surname>McGrady</surname> <given-names>G</given-names></name><name><surname>Wahl</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Conversion of peripheral CD4<sup>+</sup>CD25<sup>-</sup> naive T cells to CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells by TGF<sup>-</sup>beta induction of transcription factor Foxp3</article-title><source>Journal of Experimental Medicine</source><volume>198</volume><fpage>1875</fpage><lpage>1886</lpage><pub-id pub-id-type="doi">10.1084/jem.20030152</pub-id><pub-id pub-id-type="pmid">14676299</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Kim</surname> <given-names>YC</given-names></name><name><surname>Laurence</surname> <given-names>A</given-names></name><name><surname>Punkosdy</surname> <given-names>GA</given-names></name><name><surname>Shevach</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3<sup>+</sup> T cells in vivo</article-title><source>Journal of Immunology</source><volume>186</volume><fpage>6329</fpage><lpage>6337</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1100061</pub-id><pub-id pub-id-type="pmid">21525380</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Yang</surname> <given-names>T</given-names></name><name><surname>Zhu</surname> <given-names>L</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cellular metabolism on T-cell development and function</article-title><source>International Reviews of Immunology</source><volume>34</volume><fpage>19</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.3109/08830185.2014.902452</pub-id><pub-id pub-id-type="pmid">24708060</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>HY</given-names></name><name><surname>Chen</surname> <given-names>RH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cullin 3 ubiquitin ligases in Cancer biology: functions and therapeutic implications</article-title><source>Frontiers in Oncology</source><volume>6</volume><elocation-id>113</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2016.00113</pub-id><pub-id pub-id-type="pmid">27200299</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clough</surname> <given-names>JN</given-names></name><name><surname>Omer</surname> <given-names>OS</given-names></name><name><surname>Tasker</surname> <given-names>S</given-names></name><name><surname>Lord</surname> <given-names>GM</given-names></name><name><surname>Irving</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Regulatory T-cell therapy in Crohn's disease: challenges and advances</article-title><source>Gut</source><volume>69</volume><fpage>942</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2019-319850</pub-id><pub-id pub-id-type="pmid">31980447</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dall'Era</surname> <given-names>M</given-names></name><name><surname>Pauli</surname> <given-names>ML</given-names></name><name><surname>Remedios</surname> <given-names>K</given-names></name><name><surname>Taravati</surname> <given-names>K</given-names></name><name><surname>Sandova</surname> <given-names>PM</given-names></name><name><surname>Putnam</surname> <given-names>AL</given-names></name><name><surname>Lares</surname> <given-names>A</given-names></name><name><surname>Haemel</surname> <given-names>A</given-names></name><name><surname>Tang</surname> <given-names>Q</given-names></name><name><surname>Hellerstein</surname> <given-names>M</given-names></name><name><surname>Fitch</surname> <given-names>M</given-names></name><name><surname>McNamara</surname> <given-names>J</given-names></name><name><surname>Welch</surname> <given-names>B</given-names></name><name><surname>Bluestone</surname> <given-names>JA</given-names></name><name><surname>Wofsy</surname> <given-names>D</given-names></name><name><surname>Rosenblum</surname> <given-names>MD</given-names></name><collab>Autoimmunity Centers of Excellence</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Adoptive treg cell therapy in a patient with systemic lupus erythematosus</article-title><source>Arthritis &amp; Rheumatology</source><volume>71</volume><fpage>431</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1002/art.40737</pub-id><pub-id pub-id-type="pmid">30277008</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname> <given-names>S</given-names></name><name><surname>Morvan</surname> <given-names>F</given-names></name><name><surname>Jourde</surname> <given-names>B</given-names></name><name><surname>Meier</surname> <given-names>V</given-names></name><name><surname>Kahle</surname> <given-names>P</given-names></name><name><surname>Brebbia</surname> <given-names>P</given-names></name><name><surname>Toussaint</surname> <given-names>G</given-names></name><name><surname>Glass</surname> <given-names>DJ</given-names></name><name><surname>Fornaro</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ATP citrate lyase improves mitochondrial function in skeletal muscle</article-title><source>Cell Metabolism</source><volume>21</volume><fpage>868</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2015.05.006</pub-id><pub-id pub-id-type="pmid">26039450</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidge</surname> <given-names>B</given-names></name><name><surname>de Oliveira Rebola</surname> <given-names>KG</given-names></name><name><surname>Agbor</surname> <given-names>LN</given-names></name><name><surname>Sigmund</surname> <given-names>CD</given-names></name><name><surname>Singer</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cul3 regulates cyclin E1 protein abundance via a degron located within the N-terminal region of cyclin E</article-title><source>Journal of Cell Science</source><volume>64</volume><elocation-id>233049</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.233049</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Rosa</surname> <given-names>V</given-names></name><name><surname>Galgani</surname> <given-names>M</given-names></name><name><surname>Porcellini</surname> <given-names>A</given-names></name><name><surname>Colamatteo</surname> <given-names>A</given-names></name><name><surname>Santopaolo</surname> <given-names>M</given-names></name><name><surname>Zuchegna</surname> <given-names>C</given-names></name><name><surname>Romano</surname> <given-names>A</given-names></name><name><surname>De Simone</surname> <given-names>S</given-names></name><name><surname>Procaccini</surname> <given-names>C</given-names></name><name><surname>La Rocca</surname> <given-names>C</given-names></name><name><surname>Carrieri</surname> <given-names>PB</given-names></name><name><surname>Maniscalco</surname> <given-names>GT</given-names></name><name><surname>Salvetti</surname> <given-names>M</given-names></name><name><surname>Buscarinu</surname> <given-names>MC</given-names></name><name><surname>Franzese</surname> <given-names>A</given-names></name><name><surname>Mozzillo</surname> <given-names>E</given-names></name><name><surname>La Cava</surname> <given-names>A</given-names></name><name><surname>Matarese</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants</article-title><source>Nature Immunology</source><volume>16</volume><fpage>1174</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1038/ni.3269</pub-id><pub-id pub-id-type="pmid">26414764</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derynck</surname> <given-names>R</given-names></name><name><surname>Zhang</surname> <given-names>YE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Smad-dependent and Smad-independent pathways in TGF-beta family signalling</article-title><source>Nature</source><volume>425</volume><fpage>577</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1038/nature02006</pub-id><pub-id pub-id-type="pmid">14534577</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominguez-Villar</surname> <given-names>M</given-names></name><name><surname>Hafler</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Regulatory T cells in autoimmune disease</article-title><source>Nature Immunology</source><volume>19</volume><fpage>665</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0120-4</pub-id><pub-id pub-id-type="pmid">29925983</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Hua</surname> <given-names>ZC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A novel genotyping strategy based on allele-specific inverse PCR for rapid and reliable identification of conditional FADD knockout mice</article-title><source>Molecular Biotechnology</source><volume>38</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1007/s12033-007-9002-y</pub-id><pub-id pub-id-type="pmid">18219592</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esensten</surname> <given-names>JH</given-names></name><name><surname>Muller</surname> <given-names>YD</given-names></name><name><surname>Bluestone</surname> <given-names>JA</given-names></name><name><surname>Tang</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: the next frontier</article-title><source>Journal of Allergy and Clinical Immunology</source><volume>142</volume><fpage>1710</fpage><lpage>1718</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2018.10.015</pub-id><pub-id pub-id-type="pmid">30367909</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Essig</surname> <given-names>K</given-names></name><name><surname>Hu</surname> <given-names>D</given-names></name><name><surname>Guimaraes</surname> <given-names>JC</given-names></name><name><surname>Alterauge</surname> <given-names>D</given-names></name><name><surname>Edelmann</surname> <given-names>S</given-names></name><name><surname>Raj</surname> <given-names>T</given-names></name><name><surname>Kranich</surname> <given-names>J</given-names></name><name><surname>Behrens</surname> <given-names>G</given-names></name><name><surname>Heiseke</surname> <given-names>A</given-names></name><name><surname>Floess</surname> <given-names>S</given-names></name><name><surname>Klein</surname> <given-names>J</given-names></name><name><surname>Maiser</surname> <given-names>A</given-names></name><name><surname>Marschall</surname> <given-names>S</given-names></name><name><surname>Hrabĕ de Angelis</surname> <given-names>M</given-names></name><name><surname>Leonhardt</surname> <given-names>H</given-names></name><name><surname>Calkhoven</surname> <given-names>CF</given-names></name><name><surname>Noessner</surname> <given-names>E</given-names></name><name><surname>Brocker</surname> <given-names>T</given-names></name><name><surname>Huehn</surname> <given-names>J</given-names></name><name><surname>Krug</surname> <given-names>AB</given-names></name><name><surname>Zavolan</surname> <given-names>M</given-names></name><name><surname>Baumjohann</surname> <given-names>D</given-names></name><name><surname>Heissmeyer</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Roquin suppresses the PI3K-mTOR signaling pathway to inhibit T helper cell differentiation and conversion of treg to tfr cells</article-title><source>Immunity</source><volume>47</volume><fpage>1067</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.11.008</pub-id><pub-id pub-id-type="pmid">29246441</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Xu</surname> <given-names>S</given-names></name><name><surname>Shen</surname> <given-names>AZ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: an updated review</article-title><source>Progress in Lipid Research</source><volume>77</volume><elocation-id>101006</elocation-id><pub-id pub-id-type="doi">10.1016/j.plipres.2019.101006</pub-id><pub-id pub-id-type="pmid">31499095</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontenot</surname> <given-names>JD</given-names></name><name><surname>Gavin</surname> <given-names>MA</given-names></name><name><surname>Rudensky</surname> <given-names>AY</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Foxp3 programs the development and function of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells</article-title><source>Nature Immunology</source><volume>4</volume><fpage>330</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1038/ni904</pub-id><pub-id pub-id-type="pmid">12612578</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname> <given-names>DW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Malonyl-CoA: the regulator of fatty acid synthesis and oxidation</article-title><source>Journal of Clinical Investigation</source><volume>122</volume><fpage>1958</fpage><lpage>1959</lpage><pub-id pub-id-type="doi">10.1172/JCI63967</pub-id><pub-id pub-id-type="pmid">22833869</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furusawa</surname> <given-names>Y</given-names></name><name><surname>Obata</surname> <given-names>Y</given-names></name><name><surname>Fukuda</surname> <given-names>S</given-names></name><name><surname>Endo</surname> <given-names>TA</given-names></name><name><surname>Nakato</surname> <given-names>G</given-names></name><name><surname>Takahashi</surname> <given-names>D</given-names></name><name><surname>Nakanishi</surname> <given-names>Y</given-names></name><name><surname>Uetake</surname> <given-names>C</given-names></name><name><surname>Kato</surname> <given-names>K</given-names></name><name><surname>Kato</surname> <given-names>T</given-names></name><name><surname>Takahashi</surname> <given-names>M</given-names></name><name><surname>Fukuda</surname> <given-names>NN</given-names></name><name><surname>Murakami</surname> <given-names>S</given-names></name><name><surname>Miyauchi</surname> <given-names>E</given-names></name><name><surname>Hino</surname> <given-names>S</given-names></name><name><surname>Atarashi</surname> <given-names>K</given-names></name><name><surname>Onawa</surname> <given-names>S</given-names></name><name><surname>Fujimura</surname> <given-names>Y</given-names></name><name><surname>Lockett</surname> <given-names>T</given-names></name><name><surname>Clarke</surname> <given-names>JM</given-names></name><name><surname>Topping</surname> <given-names>DL</given-names></name><name><surname>Tomita</surname> <given-names>M</given-names></name><name><surname>Hori</surname> <given-names>S</given-names></name><name><surname>Ohara</surname> <given-names>O</given-names></name><name><surname>Morita</surname> <given-names>T</given-names></name><name><surname>Koseki</surname> <given-names>H</given-names></name><name><surname>Kikuchi</surname> <given-names>J</given-names></name><name><surname>Honda</surname> <given-names>K</given-names></name><name><surname>Hase</surname> <given-names>K</given-names></name><name><surname>Ohno</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells</article-title><source>Nature</source><volume>504</volume><fpage>446</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1038/nature12721</pub-id><pub-id pub-id-type="pmid">24226770</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galgani</surname> <given-names>M</given-names></name><name><surname>De Rosa</surname> <given-names>V</given-names></name><name><surname>Matarese</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>T cell metabolism and susceptibility to autoimmune diseases</article-title><source>Molecular Immunology</source><volume>68</volume><fpage>558</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2015.07.035</pub-id><pub-id pub-id-type="pmid">26265113</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genschik</surname> <given-names>P</given-names></name><name><surname>Sumara</surname> <given-names>I</given-names></name><name><surname>Lechner</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): cellular functions and disease implications</article-title><source>The EMBO Journal</source><volume>32</volume><fpage>2307</fpage><lpage>2320</lpage><pub-id pub-id-type="doi">10.1038/emboj.2013.173</pub-id><pub-id pub-id-type="pmid">23912815</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerriets</surname> <given-names>VA</given-names></name><name><surname>Kishton</surname> <given-names>RJ</given-names></name><name><surname>Nichols</surname> <given-names>AG</given-names></name><name><surname>Macintyre</surname> <given-names>AN</given-names></name><name><surname>Inoue</surname> <given-names>M</given-names></name><name><surname>Ilkayeva</surname> <given-names>O</given-names></name><name><surname>Winter</surname> <given-names>PS</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Priyadharshini</surname> <given-names>B</given-names></name><name><surname>Slawinska</surname> <given-names>ME</given-names></name><name><surname>Haeberli</surname> <given-names>L</given-names></name><name><surname>Huck</surname> <given-names>C</given-names></name><name><surname>Turka</surname> <given-names>LA</given-names></name><name><surname>Wood</surname> <given-names>KC</given-names></name><name><surname>Hale</surname> <given-names>LP</given-names></name><name><surname>Smith</surname> <given-names>PA</given-names></name><name><surname>Schneider</surname> <given-names>MA</given-names></name><name><surname>MacIver</surname> <given-names>NJ</given-names></name><name><surname>Locasale</surname> <given-names>JW</given-names></name><name><surname>Newgard</surname> <given-names>CB</given-names></name><name><surname>Shinohara</surname> <given-names>ML</given-names></name><name><surname>Rathmell</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Metabolic programming and PDHK1 control CD4<sup>+</sup> T cell subsets and inflammation</article-title><source>Journal of Clinical Investigation</source><volume>125</volume><fpage>194</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1172/JCI76012</pub-id><pub-id pub-id-type="pmid">25437876</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname> <given-names>S</given-names></name><name><surname>Taylor</surname> <given-names>A</given-names></name><name><surname>Chin</surname> <given-names>M</given-names></name><name><surname>Huang</surname> <given-names>HR</given-names></name><name><surname>Conery</surname> <given-names>AR</given-names></name><name><surname>Mertz</surname> <given-names>JA</given-names></name><name><surname>Salmeron</surname> <given-names>A</given-names></name><name><surname>Dakle</surname> <given-names>PJ</given-names></name><name><surname>Mele</surname> <given-names>D</given-names></name><name><surname>Cote</surname> <given-names>A</given-names></name><name><surname>Jayaram</surname> <given-names>H</given-names></name><name><surname>Setser</surname> <given-names>JW</given-names></name><name><surname>Poy</surname> <given-names>F</given-names></name><name><surname>Hatzivassiliou</surname> <given-names>G</given-names></name><name><surname>DeAlmeida-Nagata</surname> <given-names>D</given-names></name><name><surname>Sandy</surname> <given-names>P</given-names></name><name><surname>Hatton</surname> <given-names>C</given-names></name><name><surname>Romero</surname> <given-names>FA</given-names></name><name><surname>Chiang</surname> <given-names>E</given-names></name><name><surname>Reimer</surname> <given-names>T</given-names></name><name><surname>Crawford</surname> <given-names>T</given-names></name><name><surname>Pardo</surname> <given-names>E</given-names></name><name><surname>Watson</surname> <given-names>VG</given-names></name><name><surname>Tsui</surname> <given-names>V</given-names></name><name><surname>Cochran</surname> <given-names>AG</given-names></name><name><surname>Zawadzke</surname> <given-names>L</given-names></name><name><surname>Harmange</surname> <given-names>JC</given-names></name><name><surname>Audia</surname> <given-names>JE</given-names></name><name><surname>Bryant</surname> <given-names>BM</given-names></name><name><surname>Cummings</surname> <given-names>RT</given-names></name><name><surname>Magnuson</surname> <given-names>SR</given-names></name><name><surname>Grogan</surname> <given-names>JL</given-names></name><name><surname>Bellon</surname> <given-names>SF</given-names></name><name><surname>Albrecht</surname> <given-names>BK</given-names></name><name><surname>Sims</surname> <given-names>RJ</given-names></name><name><surname>Lora</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Regulatory T cell modulation by CBP/EP300 bromodomain inhibition</article-title><source>Journal of Biological Chemistry</source><volume>291</volume><fpage>13014</fpage><lpage>13027</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.708560</pub-id><pub-id pub-id-type="pmid">27056325</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Göschl</surname> <given-names>L</given-names></name><name><surname>Scheinecker</surname> <given-names>C</given-names></name><name><surname>Bonelli</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Treg cells in autoimmunity: from identification to Treg-based therapies</article-title><source>Seminars in Immunopathology</source><volume>41</volume><fpage>301</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1007/s00281-019-00741-8</pub-id><pub-id pub-id-type="pmid">30953162</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gualdoni</surname> <given-names>GA</given-names></name><name><surname>Mayer</surname> <given-names>KA</given-names></name><name><surname>Göschl</surname> <given-names>L</given-names></name><name><surname>Boucheron</surname> <given-names>N</given-names></name><name><surname>Ellmeier</surname> <given-names>W</given-names></name><name><surname>Zlabinger</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The AMP analog AICAR modulates the treg/Th17 Axis through enhancement of fatty acid oxidation</article-title><source>Faseb J</source><volume>30</volume><fpage>3800</fpage><lpage>3809</lpage><pub-id pub-id-type="doi">10.1096/fj.201600522R</pub-id><pub-id pub-id-type="pmid">27492924</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>ZS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Impact of metabolism on T-cell differentiation and function and cross talk with tumor microenvironment</article-title><source>Frontiers in Immunology</source><volume>8</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00270</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname> <given-names>C</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Choi</surname> <given-names>HH</given-names></name><name><surname>Baddour</surname> <given-names>J</given-names></name><name><surname>Achreja</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Wan</surname> <given-names>G</given-names></name><name><surname>Huang</surname> <given-names>C</given-names></name><name><surname>Ji</surname> <given-names>G</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Nagrath</surname> <given-names>D</given-names></name><name><surname>Lu</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Amplification of USP13 drives ovarian Cancer metabolism</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>13525</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms13525</pub-id><pub-id pub-id-type="pmid">27892457</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname> <given-names>F</given-names></name><name><surname>Tian</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Jin</surname> <given-names>X</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Peng</surname> <given-names>P</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Xia</surname> <given-names>C</given-names></name><name><surname>Feng</surname> <given-names>Y</given-names></name><name><surname>Wei</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Butyrate enhances CPT1A activity to promote fatty acid oxidation and iTreg differentiation</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2014681118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2014681118</pub-id><pub-id pub-id-type="pmid">34035164</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname> <given-names>S</given-names></name><name><surname>Nomura</surname> <given-names>T</given-names></name><name><surname>Sakaguchi</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Control of regulatory T cell development by the transcription factor Foxp3</article-title><source>Science</source><volume>299</volume><fpage>1057</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1126/science.1079490</pub-id><pub-id pub-id-type="pmid">12522256</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>Q</given-names></name><name><surname>Xu</surname> <given-names>L</given-names></name><name><surname>Ye</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>T cell immune response within B-cell follicles</article-title><source>Advances in Immunology in China - Part A</source><volume>144</volume><fpage>155</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/bs.ai.2019.08.008</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iacobazzi</surname> <given-names>V</given-names></name><name><surname>Infantino</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Citrate--new functions for an old metabolite</article-title><source>Biological Chemistry</source><volume>395</volume><fpage>387</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1515/hsz-2013-0271</pub-id><pub-id pub-id-type="pmid">24445237</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izcue</surname> <given-names>A</given-names></name><name><surname>Coombes</surname> <given-names>JL</given-names></name><name><surname>Powrie</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation</article-title><source>Immunological Reviews</source><volume>212</volume><fpage>256</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1111/j.0105-2896.2006.00423.x</pub-id><pub-id pub-id-type="pmid">16903919</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>MO</given-names></name><name><surname>Wolf</surname> <given-names>MM</given-names></name><name><surname>Madden</surname> <given-names>MZ</given-names></name><name><surname>Andrejeva</surname> <given-names>G</given-names></name><name><surname>Sugiura</surname> <given-names>A</given-names></name><name><surname>Contreras</surname> <given-names>DC</given-names></name><name><surname>Maseda</surname> <given-names>D</given-names></name><name><surname>Liberti</surname> <given-names>MV</given-names></name><name><surname>Paz</surname> <given-names>K</given-names></name><name><surname>Kishton</surname> <given-names>RJ</given-names></name><name><surname>Johnson</surname> <given-names>ME</given-names></name><name><surname>de Cubas</surname> <given-names>AA</given-names></name><name><surname>Wu</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Newcomb</surname> <given-names>DC</given-names></name><name><surname>Wells</surname> <given-names>AD</given-names></name><name><surname>Restifo</surname> <given-names>NP</given-names></name><name><surname>Rathmell</surname> <given-names>WK</given-names></name><name><surname>Locasale</surname> <given-names>JW</given-names></name><name><surname>Davila</surname> <given-names>ML</given-names></name><name><surname>Blazar</surname> <given-names>BR</given-names></name><name><surname>Rathmell</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Distinct regulation of Th17 and Th1 cell differentiation by Glutaminase-Dependent metabolism</article-title><source>Cell</source><volume>175</volume><fpage>1780</fpage><lpage>1795</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.10.001</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempkes</surname> <given-names>RWM</given-names></name><name><surname>Joosten</surname> <given-names>I</given-names></name><name><surname>Koenen</surname> <given-names>H</given-names></name><name><surname>He</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metabolic pathways involved in regulatory T cell functionality</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>2839</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.02839</pub-id><pub-id pub-id-type="pmid">31849995</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kidani</surname> <given-names>Y</given-names></name><name><surname>Elsaesser</surname> <given-names>H</given-names></name><name><surname>Hock</surname> <given-names>MB</given-names></name><name><surname>Vergnes</surname> <given-names>L</given-names></name><name><surname>Williams</surname> <given-names>KJ</given-names></name><name><surname>Argus</surname> <given-names>JP</given-names></name><name><surname>Marbois</surname> <given-names>BN</given-names></name><name><surname>Komisopoulou</surname> <given-names>E</given-names></name><name><surname>Wilson</surname> <given-names>EB</given-names></name><name><surname>Osborne</surname> <given-names>TF</given-names></name><name><surname>Graeber</surname> <given-names>TG</given-names></name><name><surname>Reue</surname> <given-names>K</given-names></name><name><surname>Brooks</surname> <given-names>DG</given-names></name><name><surname>Bensinger</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity</article-title><source>Nature Immunology</source><volume>14</volume><fpage>489</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1038/ni.2570</pub-id><pub-id pub-id-type="pmid">23563690</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kordowski</surname> <given-names>A</given-names></name><name><surname>Reinicke</surname> <given-names>AT</given-names></name><name><surname>Wu</surname> <given-names>D</given-names></name><name><surname>Orinska</surname> <given-names>Z</given-names></name><name><surname>Hagemann</surname> <given-names>P</given-names></name><name><surname>Huber-Lang</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>JB</given-names></name><name><surname>Wang</surname> <given-names>YH</given-names></name><name><surname>Hogan</surname> <given-names>SP</given-names></name><name><surname>Köhl</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>C5a receptor 1<sup>−/−</sup> mice are protected from the development of IgE-mediated experimental food allergy</article-title><source>Allergy Eur J Allergy Clin Immunol</source><volume>74</volume><fpage>767</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1111/all.13637</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>YK</given-names></name><name><surname>Mukasa</surname> <given-names>R</given-names></name><name><surname>Hatton</surname> <given-names>RD</given-names></name><name><surname>Weaver</surname> <given-names>CT</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Developmental plasticity of Th17 and treg cells</article-title><source>Current Opinion in Immunology</source><volume>21</volume><fpage>274</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2009.05.021</pub-id><pub-id pub-id-type="pmid">19524429</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Gong</surname> <given-names>W</given-names></name><name><surname>Lazenby</surname> <given-names>AJ</given-names></name><name><surname>Swanson</surname> <given-names>BJ</given-names></name><name><surname>Herring</surname> <given-names>LE</given-names></name><name><surname>Asara</surname> <given-names>JM</given-names></name><name><surname>Singer</surname> <given-names>JD</given-names></name><name><surname>Wen</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Myeloid-derived cullin 3 promotes STAT3 phosphorylation by inhibiting OGT expression and protects against intestinal inflammation</article-title><source>Journal of Experimental Medicine</source><volume>214</volume><fpage>1093</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1084/jem.20161105</pub-id><pub-id pub-id-type="pmid">28280036</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>R</given-names></name><name><surname>Tao</surname> <given-names>R</given-names></name><name><surname>Gao</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>T</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Guan</surname> <given-names>KL</given-names></name><name><surname>Xiong</surname> <given-names>Y</given-names></name><name><surname>Lei</surname> <given-names>QY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth</article-title><source>Molecular Cell</source><volume>51</volume><fpage>506</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.07.002</pub-id><pub-id pub-id-type="pmid">23932781</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>HP</given-names></name><name><surname>Cheng</surname> <given-names>ZL</given-names></name><name><surname>He</surname> <given-names>RY</given-names></name><name><surname>Song</surname> <given-names>L</given-names></name><name><surname>Tian</surname> <given-names>MX</given-names></name><name><surname>Zhou</surname> <given-names>LS</given-names></name><name><surname>Groh</surname> <given-names>BS</given-names></name><name><surname>Liu</surname> <given-names>WR</given-names></name><name><surname>Ji</surname> <given-names>MB</given-names></name><name><surname>Ding</surname> <given-names>C</given-names></name><name><surname>Shi</surname> <given-names>YH</given-names></name><name><surname>Guan</surname> <given-names>KL</given-names></name><name><surname>Ye</surname> <given-names>D</given-names></name><name><surname>Xiong</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Destabilization of fatty acid synthase by acetylation inhibits de novo lipogenesis and tumor cell growth</article-title><source>Cancer Research</source><volume>76</volume><fpage>6924</fpage><lpage>6936</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-1597</pub-id><pub-id pub-id-type="pmid">27758890</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>W</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Xu</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sirtuin4 suppresses the anti-neuroinflammatory activity of infiltrating regulatory T cells in the traumatically injured spinal cord</article-title><source>Immunology</source><volume>158</volume><fpage>362</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1111/imm.13123</pub-id><pub-id pub-id-type="pmid">31559637</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Qian</surname> <given-names>C</given-names></name><name><surname>Cao</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Post-Translational modification control of innate immunity</article-title><source>Immunity</source><volume>45</volume><fpage>15</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.06.020</pub-id><pub-id pub-id-type="pmid">27438764</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lochner</surname> <given-names>M</given-names></name><name><surname>Berod</surname> <given-names>L</given-names></name><name><surname>Sparwasser</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Fatty acid metabolism in the regulation of T cell function</article-title><source>Trends in Immunology</source><volume>36</volume><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.it.2014.12.005</pub-id><pub-id pub-id-type="pmid">25592731</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>EH</given-names></name><name><surname>Poffenberger</surname> <given-names>MC</given-names></name><name><surname>Wong</surname> <given-names>AH</given-names></name><name><surname>Jones</surname> <given-names>RG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The role of AMPK in T cell metabolism and function</article-title><source>Current Opinion in Immunology</source><volume>46</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2017.04.004</pub-id><pub-id pub-id-type="pmid">28460345</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maciolek</surname> <given-names>JA</given-names></name><name><surname>Pasternak</surname> <given-names>JA</given-names></name><name><surname>Wilson</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Metabolism of activated T lymphocytes</article-title><source>Current Opinion in Immunology</source><volume>27</volume><fpage>60</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2014.01.006</pub-id><pub-id pub-id-type="pmid">24556090</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacIver</surname> <given-names>NJ</given-names></name><name><surname>Michalek</surname> <given-names>RD</given-names></name><name><surname>Rathmell</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Metabolic regulation of T lymphocytes</article-title><source>Annual Review of Immunology</source><volume>31</volume><fpage>259</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-095956</pub-id><pub-id pub-id-type="pmid">23298210</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maekawa</surname> <given-names>M</given-names></name><name><surname>Tanigawa</surname> <given-names>K</given-names></name><name><surname>Sakaue</surname> <given-names>T</given-names></name><name><surname>Hiyoshi</surname> <given-names>H</given-names></name><name><surname>Kubota</surname> <given-names>E</given-names></name><name><surname>Joh</surname> <given-names>T</given-names></name><name><surname>Watanabe</surname> <given-names>Y</given-names></name><name><surname>Taguchi</surname> <given-names>T</given-names></name><name><surname>Higashiyama</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cullin-3 and its adaptor protein ANKFY1 determine the surface level of integrin β1 in endothelial cells</article-title><source>Biology Open</source><volume>6</volume><fpage>1707</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.1242/bio.029579</pub-id><pub-id pub-id-type="pmid">29038302</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantei</surname> <given-names>A</given-names></name><name><surname>Rutz</surname> <given-names>S</given-names></name><name><surname>Janke</surname> <given-names>M</given-names></name><name><surname>Kirchhoff</surname> <given-names>D</given-names></name><name><surname>Jung</surname> <given-names>U</given-names></name><name><surname>Patzel</surname> <given-names>V</given-names></name><name><surname>Vogel</surname> <given-names>U</given-names></name><name><surname>Rudel</surname> <given-names>T</given-names></name><name><surname>Andreou</surname> <given-names>I</given-names></name><name><surname>Weber</surname> <given-names>M</given-names></name><name><surname>Scheffold</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>siRNA stabilization prolongs gene knockdown in primary T lymphocytes</article-title><source>European Journal of Immunology</source><volume>38</volume><fpage>2616</fpage><lpage>2625</lpage><pub-id pub-id-type="doi">10.1002/eji.200738075</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname> <given-names>R</given-names></name><name><surname>Seiler</surname> <given-names>MP</given-names></name><name><surname>Scanlon</surname> <given-names>ST</given-names></name><name><surname>Mao</surname> <given-names>AP</given-names></name><name><surname>Constantinides</surname> <given-names>MG</given-names></name><name><surname>Bertozzi-Villa</surname> <given-names>C</given-names></name><name><surname>Singer</surname> <given-names>JD</given-names></name><name><surname>Bendelac</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>BTB-ZF factors recruit the E3 ligase cullin 3 to regulate lymphoid effector programs</article-title><source>Nature</source><volume>491</volume><fpage>618</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1038/nature11548</pub-id><pub-id pub-id-type="pmid">23086144</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McEvoy</surname> <given-names>JD</given-names></name><name><surname>Kossatz</surname> <given-names>U</given-names></name><name><surname>Malek</surname> <given-names>N</given-names></name><name><surname>Singer</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Constitutive turnover of cyclin E by Cul3 maintains quiescence</article-title><source>Molecular and Cellular Biology</source><volume>27</volume><fpage>3651</fpage><lpage>3666</lpage><pub-id pub-id-type="doi">10.1128/MCB.00720-06</pub-id><pub-id pub-id-type="pmid">17339333</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalek</surname> <given-names>RD</given-names></name><name><surname>Gerriets</surname> <given-names>VA</given-names></name><name><surname>Jacobs</surname> <given-names>SR</given-names></name><name><surname>Macintyre</surname> <given-names>AN</given-names></name><name><surname>MacIver</surname> <given-names>NJ</given-names></name><name><surname>Mason</surname> <given-names>EF</given-names></name><name><surname>Sullivan</surname> <given-names>SA</given-names></name><name><surname>Nichols</surname> <given-names>AG</given-names></name><name><surname>Rathmell</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4<sup>+</sup> T cell subsets</article-title><source>The Journal of Immunology</source><volume>186</volume><fpage>3299</fpage><lpage>3303</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1003613</pub-id><pub-id pub-id-type="pmid">21317389</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migita</surname> <given-names>T</given-names></name><name><surname>Narita</surname> <given-names>T</given-names></name><name><surname>Nomura</surname> <given-names>K</given-names></name><name><surname>Miyagi</surname> <given-names>E</given-names></name><name><surname>Inazuka</surname> <given-names>F</given-names></name><name><surname>Matsuura</surname> <given-names>M</given-names></name><name><surname>Ushijima</surname> <given-names>M</given-names></name><name><surname>Mashima</surname> <given-names>T</given-names></name><name><surname>Seimiya</surname> <given-names>H</given-names></name><name><surname>Satoh</surname> <given-names>Y</given-names></name><name><surname>Okumura</surname> <given-names>S</given-names></name><name><surname>Nakagawa</surname> <given-names>K</given-names></name><name><surname>Ishikawa</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>ATP citrate lyase: activation and therapeutic implications in non-small cell lung Cancer</article-title><source>Cancer Research</source><volume>68</volume><fpage>8547</fpage><lpage>8554</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-1235</pub-id><pub-id pub-id-type="pmid">18922930</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murai</surname> <given-names>M</given-names></name><name><surname>Krause</surname> <given-names>P</given-names></name><name><surname>Cheroutre</surname> <given-names>H</given-names></name><name><surname>Kronenberg</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regulatory T-cell stability and plasticity in mucosal and systemic immune systems</article-title><source>Mucosal Immunology</source><volume>3</volume><fpage>443</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1038/mi.2010.27</pub-id><pub-id pub-id-type="pmid">20505662</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noack</surname> <given-names>M</given-names></name><name><surname>Miossec</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Th17 and regulatory T cell balance in autoimmune and inflammatory diseases</article-title><source>Autoimmunity Reviews</source><volume>13</volume><fpage>668</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2013.12.004</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Connor</surname> <given-names>RS</given-names></name><name><surname>Guo</surname> <given-names>L</given-names></name><name><surname>Ghassemi</surname> <given-names>S</given-names></name><name><surname>Snyder</surname> <given-names>NW</given-names></name><name><surname>Worth</surname> <given-names>AJ</given-names></name><name><surname>Weng</surname> <given-names>L</given-names></name><name><surname>Kam</surname> <given-names>Y</given-names></name><name><surname>Philipson</surname> <given-names>B</given-names></name><name><surname>Trefely</surname> <given-names>S</given-names></name><name><surname>Nunez-Cruz</surname> <given-names>S</given-names></name><name><surname>Blair</surname> <given-names>IA</given-names></name><name><surname>June</surname> <given-names>CH</given-names></name><name><surname>Milone</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>6289</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-24676-6</pub-id><pub-id pub-id-type="pmid">29674640</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname> <given-names>CH</given-names></name><name><surname>Powell</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting T cell metabolism to regulate T cell activation, differentiation and function in disease</article-title><source>Current Opinion in Immunology</source><volume>46</volume><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2017.04.006</pub-id><pub-id pub-id-type="pmid">28521236</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinkosky</surname> <given-names>SL</given-names></name><name><surname>Newton</surname> <given-names>RS</given-names></name><name><surname>Day</surname> <given-names>EA</given-names></name><name><surname>Ford</surname> <given-names>RJ</given-names></name><name><surname>Lhotak</surname> <given-names>S</given-names></name><name><surname>Austin</surname> <given-names>RC</given-names></name><name><surname>Birch</surname> <given-names>CM</given-names></name><name><surname>Smith</surname> <given-names>BK</given-names></name><name><surname>Filippov</surname> <given-names>S</given-names></name><name><surname>Groot</surname> <given-names>PHE</given-names></name><name><surname>Steinberg</surname> <given-names>GR</given-names></name><name><surname>Lalwani</surname> <given-names>ND</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>13457</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms13457</pub-id><pub-id pub-id-type="pmid">27892461</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priyadharshini</surname> <given-names>B</given-names></name><name><surname>Loschi</surname> <given-names>M</given-names></name><name><surname>Newton</surname> <given-names>RH</given-names></name><name><surname>Zhang</surname> <given-names>JW</given-names></name><name><surname>Finn</surname> <given-names>KK</given-names></name><name><surname>Gerriets</surname> <given-names>VA</given-names></name><name><surname>Huynh</surname> <given-names>A</given-names></name><name><surname>Rathmell</surname> <given-names>JC</given-names></name><name><surname>Blazar</surname> <given-names>BR</given-names></name><name><surname>Turka</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cutting edge: tgf-β and phosphatidylinositol 3-Kinase signals modulate distinct metabolism of regulatory T cell subsets</article-title><source>The Journal of Immunology</source><volume>201</volume><fpage>2215</fpage><lpage>2219</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1800311</pub-id><pub-id pub-id-type="pmid">30209190</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Heredia</surname> <given-names>JE</given-names></name><name><surname>Altarejos</surname> <given-names>JY</given-names></name><name><surname>Screaton</surname> <given-names>R</given-names></name><name><surname>Goebel</surname> <given-names>N</given-names></name><name><surname>Niessen</surname> <given-names>S</given-names></name><name><surname>Macleod</surname> <given-names>IX</given-names></name><name><surname>Liew</surname> <given-names>CW</given-names></name><name><surname>Kulkarni</surname> <given-names>RN</given-names></name><name><surname>Bain</surname> <given-names>J</given-names></name><name><surname>Newgard</surname> <given-names>C</given-names></name><name><surname>Nelson</surname> <given-names>M</given-names></name><name><surname>Evans</surname> <given-names>RM</given-names></name><name><surname>Yates</surname> <given-names>J</given-names></name><name><surname>Montminy</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism</article-title><source>Science</source><volume>312</volume><fpage>1763</fpage><lpage>1766</lpage><pub-id pub-id-type="doi">10.1126/science.1123374</pub-id><pub-id pub-id-type="pmid">16794074</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raud</surname> <given-names>B</given-names></name><name><surname>Roy</surname> <given-names>DG</given-names></name><name><surname>Divakaruni</surname> <given-names>AS</given-names></name><name><surname>Tarasenko</surname> <given-names>TN</given-names></name><name><surname>Franke</surname> <given-names>R</given-names></name><name><surname>Ma</surname> <given-names>EH</given-names></name><name><surname>Samborska</surname> <given-names>B</given-names></name><name><surname>Hsieh</surname> <given-names>WY</given-names></name><name><surname>Wong</surname> <given-names>AH</given-names></name><name><surname>Stüve</surname> <given-names>P</given-names></name><name><surname>Arnold-Schrauf</surname> <given-names>C</given-names></name><name><surname>Guderian</surname> <given-names>M</given-names></name><name><surname>Lochner</surname> <given-names>M</given-names></name><name><surname>Rampertaap</surname> <given-names>S</given-names></name><name><surname>Romito</surname> <given-names>K</given-names></name><name><surname>Monsale</surname> <given-names>J</given-names></name><name><surname>Brönstrup</surname> <given-names>M</given-names></name><name><surname>Bensinger</surname> <given-names>SJ</given-names></name><name><surname>Murphy</surname> <given-names>AN</given-names></name><name><surname>McGuire</surname> <given-names>PJ</given-names></name><name><surname>Jones</surname> <given-names>RG</given-names></name><name><surname>Sparwasser</surname> <given-names>T</given-names></name><name><surname>Berod</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Etomoxir actions on regulatory and memory T cells are independent of Cpt1a-Mediated fatty acid oxidation</article-title><source>Cell Metabolism</source><volume>28</volume><fpage>504</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.06.002</pub-id><pub-id pub-id-type="pmid">30043753</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryba-Stanisławowska</surname> <given-names>M</given-names></name><name><surname>Sakowska</surname> <given-names>J</given-names></name><name><surname>Zieliński</surname> <given-names>M</given-names></name><name><surname>Ławrynowicz</surname> <given-names>U</given-names></name><name><surname>Trzonkowski</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Regulatory T cells: the future of autoimmune disease treatment</article-title><source>Expert Review of Clinical Immunology</source><volume>15</volume><fpage>777</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1080/1744666X.2019.1620602</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname> <given-names>S</given-names></name><name><surname>Yamaguchi</surname> <given-names>T</given-names></name><name><surname>Nomura</surname> <given-names>T</given-names></name><name><surname>Ono</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Regulatory T cells and immune tolerance</article-title><source>Cell</source><volume>133</volume><fpage>775</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.05.009</pub-id><pub-id pub-id-type="pmid">18510923</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saravia</surname> <given-names>J</given-names></name><name><surname>Zeng</surname> <given-names>H</given-names></name><name><surname>Dhungana</surname> <given-names>Y</given-names></name><name><surname>Bastardo Blanco</surname> <given-names>D</given-names></name><name><surname>Nguyen</surname> <given-names>TM</given-names></name><name><surname>Chapman</surname> <given-names>NM</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Kanneganti</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Raynor</surname> <given-names>JL</given-names></name><name><surname>Vogel</surname> <given-names>P</given-names></name><name><surname>Neale</surname> <given-names>G</given-names></name><name><surname>Carmeliet</surname> <given-names>P</given-names></name><name><surname>Chi</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Homeostasis and transitional activation of regulatory T cells require c-Myc</article-title><source>Science Advances</source><volume>6</volume><elocation-id>eaaw6443</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aaw6443</pub-id><pub-id pub-id-type="pmid">31911938</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saritas</surname> <given-names>T</given-names></name><name><surname>Cuevas</surname> <given-names>CA</given-names></name><name><surname>Ferdaus</surname> <given-names>MZ</given-names></name><name><surname>Kuppe</surname> <given-names>C</given-names></name><name><surname>Kramann</surname> <given-names>R</given-names></name><name><surname>Moeller</surname> <given-names>MJ</given-names></name><name><surname>Floege</surname> <given-names>J</given-names></name><name><surname>Singer</surname> <given-names>JD</given-names></name><name><surname>McCormick</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Disruption of CUL3-mediated ubiquitination causes proximal tubule injury and kidney fibrosis</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>4596</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-40795-0</pub-id><pub-id pub-id-type="pmid">30872636</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlenner</surname> <given-names>SM</given-names></name><name><surname>Weigmann</surname> <given-names>B</given-names></name><name><surname>Ruan</surname> <given-names>Q</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>von Boehmer</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Smad3 binding to the foxp3 enhancer is dispensable for the development of regulatory T cells with the exception of the gut</article-title><source>Journal of Experimental Medicine</source><volume>209</volume><fpage>1529</fpage><lpage>1535</lpage><pub-id pub-id-type="doi">10.1084/jem.20112646</pub-id><pub-id pub-id-type="pmid">22908322</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider-Poetsch</surname> <given-names>T</given-names></name><name><surname>Ju</surname> <given-names>J</given-names></name><name><surname>Eyler</surname> <given-names>DE</given-names></name><name><surname>Dang</surname> <given-names>Y</given-names></name><name><surname>Bhat</surname> <given-names>S</given-names></name><name><surname>Merrick</surname> <given-names>WC</given-names></name><name><surname>Green</surname> <given-names>R</given-names></name><name><surname>Shen</surname> <given-names>B</given-names></name><name><surname>Liu</surname> <given-names>JO</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin</article-title><source>Nature Chemical Biology</source><volume>6</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1038/nchembio.304</pub-id><pub-id pub-id-type="pmid">20118940</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>LZ</given-names></name><name><surname>Wang</surname> <given-names>R</given-names></name><name><surname>Huang</surname> <given-names>G</given-names></name><name><surname>Vogel</surname> <given-names>P</given-names></name><name><surname>Neale</surname> <given-names>G</given-names></name><name><surname>Green</surname> <given-names>DR</given-names></name><name><surname>Chi</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and treg cells</article-title><source>Journal of Experimental Medicine</source><volume>208</volume><fpage>1367</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1084/jem.20110278</pub-id><pub-id pub-id-type="pmid">21708926</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname> <given-names>JD</given-names></name><name><surname>Gurian-West</surname> <given-names>M</given-names></name><name><surname>Clurman</surname> <given-names>B</given-names></name><name><surname>Roberts</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells</article-title><source>Genes &amp; Development</source><volume>13</volume><fpage>2375</fpage><lpage>2387</lpage><pub-id pub-id-type="doi">10.1101/gad.13.18.2375</pub-id><pub-id pub-id-type="pmid">10500095</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivanand</surname> <given-names>S</given-names></name><name><surname>Rhoades</surname> <given-names>S</given-names></name><name><surname>Jiang</surname> <given-names>Q</given-names></name><name><surname>Lee</surname> <given-names>JV</given-names></name><name><surname>Benci</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Yuan</surname> <given-names>S</given-names></name><name><surname>Viney</surname> <given-names>I</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Carrer</surname> <given-names>A</given-names></name><name><surname>Bennett</surname> <given-names>MJ</given-names></name><name><surname>Minn</surname> <given-names>AJ</given-names></name><name><surname>Weljie</surname> <given-names>AM</given-names></name><name><surname>Greenberg</surname> <given-names>RA</given-names></name><name><surname>Wellen</surname> <given-names>KE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Nuclear Acetyl-CoA production by ACLY promotes homologous recombination</article-title><source>Molecular Cell</source><volume>67</volume><fpage>252</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.06.008</pub-id><pub-id pub-id-type="pmid">28689661</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souchelnytskyi</surname> <given-names>S</given-names></name><name><surname>Tamaki</surname> <given-names>K</given-names></name><name><surname>Engström</surname> <given-names>U</given-names></name><name><surname>Wernstedt</surname> <given-names>C</given-names></name><name><surname>ten Dijke</surname> <given-names>P</given-names></name><name><surname>Heldin</surname> <given-names>CH</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling</article-title><source>Journal of Biological Chemistry</source><volume>272</volume><fpage>28107</fpage><lpage>28115</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.44.28107</pub-id><pub-id pub-id-type="pmid">9346966</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Oravecz-Wilson</surname> <given-names>K</given-names></name><name><surname>Mathewson</surname> <given-names>N</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>McEachin</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Toubai</surname> <given-names>T</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Rossi</surname> <given-names>C</given-names></name><name><surname>Braun</surname> <given-names>T</given-names></name><name><surname>Saunders</surname> <given-names>T</given-names></name><name><surname>Reddy</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mature T cell responses are controlled by microRNA-142</article-title><source>Journal of Clinical Investigation</source><volume>125</volume><fpage>2825</fpage><lpage>2840</lpage><pub-id pub-id-type="doi">10.1172/JCI78753</pub-id><pub-id pub-id-type="pmid">26098216</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname> <given-names>JH</given-names></name><name><surname>Cheng</surname> <given-names>M</given-names></name><name><surname>Tang</surname> <given-names>JP</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Pan</surname> <given-names>F</given-names></name><name><surname>Li</surname> <given-names>XP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Foxp3, regulatory T cell, and autoimmune diseases</article-title><source>Inflammation</source><volume>40</volume><fpage>328</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1007/s10753-016-0470-8</pub-id><pub-id pub-id-type="pmid">27882473</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Herk</surname> <given-names>EH</given-names></name><name><surname>Te Velde</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Treg subsets in inflammatory bowel disease and colorectal carcinoma: characteristics, role, and therapeutic targets</article-title><source>Journal of Gastroenterology and Hepatology</source><volume>31</volume><fpage>1393</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1111/jgh.13342</pub-id><pub-id pub-id-type="pmid">26990130</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Ark</surname> <given-names>A</given-names></name><name><surname>Cao</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TGF-β receptors: in and beyond TGF-β signaling</article-title><source>Cellular Signalling</source><volume>52</volume><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2018.09.002</pub-id><pub-id pub-id-type="pmid">30184463</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>R</given-names></name><name><surname>Dillon</surname> <given-names>CP</given-names></name><name><surname>Shi</surname> <given-names>LZ</given-names></name><name><surname>Milasta</surname> <given-names>S</given-names></name><name><surname>Carter</surname> <given-names>R</given-names></name><name><surname>Finkelstein</surname> <given-names>D</given-names></name><name><surname>McCormick</surname> <given-names>LL</given-names></name><name><surname>Fitzgerald</surname> <given-names>P</given-names></name><name><surname>Chi</surname> <given-names>H</given-names></name><name><surname>Munger</surname> <given-names>J</given-names></name><name><surname>Green</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The transcription factor myc controls metabolic reprogramming upon T lymphocyte activation</article-title><source>Immunity</source><volume>35</volume><fpage>871</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.09.021</pub-id><pub-id pub-id-type="pmid">22195744</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>M</given-names></name><name><surname>Yang</surname> <given-names>IV</given-names></name><name><surname>Davidson</surname> <given-names>EJ</given-names></name><name><surname>Joetham</surname> <given-names>A</given-names></name><name><surname>Takeda</surname> <given-names>K</given-names></name><name><surname>O'Connor</surname> <given-names>BP</given-names></name><name><surname>Gelfand</surname> <given-names>EW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Forkhead box protein 3 demethylation is associated with tolerance induction in peanut-induced intestinal allergy</article-title><source>Journal of Allergy and Clinical Immunology</source><volume>141</volume><fpage>659</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2017.04.020</pub-id><pub-id pub-id-type="pmid">28479331</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Qian</surname> <given-names>J</given-names></name><name><surname>Sun</surname> <given-names>F</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Ye</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Du</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bidirectional regulation between 1st trimester HTR8/SVneo trophoblast cells and in vitro differentiated Th17/Treg cells suggest a fetal-maternal regulatory loop in human pregnancy</article-title><source>American Journal of Reproductive Immunology</source><volume>81</volume><elocation-id>e13106</elocation-id><pub-id pub-id-type="doi">10.1111/aji.13106</pub-id><pub-id pub-id-type="pmid">30811743</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>R</given-names></name><name><surname>Solt</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Metabolism of murine TH 17 cells: impact on cell fate and function</article-title><source>European Journal of Immunology</source><volume>46</volume><fpage>807</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1002/eji.201545788</pub-id><pub-id pub-id-type="pmid">26893133</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirtz</surname> <given-names>S</given-names></name><name><surname>Neufert</surname> <given-names>C</given-names></name><name><surname>Weigmann</surname> <given-names>B</given-names></name><name><surname>Neurath</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Chemically induced mouse models of intestinal inflammation</article-title><source>Nature Protocols</source><volume>2</volume><fpage>541</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.41</pub-id><pub-id pub-id-type="pmid">17406617</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirtz</surname> <given-names>S</given-names></name><name><surname>Popp</surname> <given-names>V</given-names></name><name><surname>Kindermann</surname> <given-names>M</given-names></name><name><surname>Gerlach</surname> <given-names>K</given-names></name><name><surname>Weigmann</surname> <given-names>B</given-names></name><name><surname>Fichtner-Feigl</surname> <given-names>S</given-names></name><name><surname>Neurath</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Chemically induced mouse models of acute and chronic intestinal inflammation</article-title><source>Nature Protocols</source><volume>12</volume><fpage>1295</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1038/nprot.2017.044</pub-id><pub-id pub-id-type="pmid">28569761</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirtz</surname> <given-names>S</given-names></name><name><surname>Neurath</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mouse models of inflammatory bowel disease</article-title><source>Advanced Drug Delivery Reviews</source><volume>59</volume><fpage>1073</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2007.07.003</pub-id><pub-id pub-id-type="pmid">17825455</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfgang</surname> <given-names>MJ</given-names></name><name><surname>Lane</surname> <given-names>MD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The role of hypothalamic malonyl-CoA in energy homeostasis</article-title><source>Journal of Biological Chemistry</source><volume>281</volume><fpage>37265</fpage><lpage>37269</lpage><pub-id pub-id-type="doi">10.1074/jbc.R600016200</pub-id><pub-id pub-id-type="pmid">17018521</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname> <given-names>T</given-names></name><name><surname>Matsunami</surname> <given-names>E</given-names></name><name><surname>Komori</surname> <given-names>K</given-names></name><name><surname>Hayashi</surname> <given-names>S</given-names></name><name><surname>Kadowaki</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The isoflavone puerarin induces Foxp3<sup>+</sup> regulatory T cells by augmenting retinoic acid production, thereby inducing mucosal immune tolerance in a murine food allergy model</article-title><source>Biochemical and Biophysical Research Communications</source><volume>516</volume><fpage>626</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.06.051</pub-id><pub-id pub-id-type="pmid">31235250</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaidi</surname> <given-names>N</given-names></name><name><surname>Swinnen</surname> <given-names>JV</given-names></name><name><surname>Smans</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>ATP-citrate lyase: a key player in Cancer metabolism</article-title><source>Cancer Research</source><volume>72</volume><fpage>3709</fpage><lpage>3714</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-4112</pub-id><pub-id pub-id-type="pmid">22787121</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Huang</surname> <given-names>G</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Yue</surname> <given-names>X</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Zhu</surname> <given-names>J</given-names></name><name><surname>Shen</surname> <given-names>Z</given-names></name><name><surname>Haffty</surname> <given-names>BG</given-names></name><name><surname>Hu</surname> <given-names>W</given-names></name><name><surname>Feng</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression</article-title><source>Genes &amp; Development</source><volume>30</volume><fpage>1956</fpage><lpage>1970</lpage><pub-id pub-id-type="doi">10.1101/gad.283283.116</pub-id><pub-id pub-id-type="pmid">27664236</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>YE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Non-Smad signaling pathways of the TGF-β family</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>9</volume><elocation-id>a022129</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a022129</pub-id><pub-id pub-id-type="pmid">27864313</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>D</given-names></name><name><surname>Chia</surname> <given-names>C</given-names></name><name><surname>Jiao</surname> <given-names>X</given-names></name><name><surname>Jin</surname> <given-names>W</given-names></name><name><surname>Kasagi</surname> <given-names>S</given-names></name><name><surname>Wu</surname> <given-names>R</given-names></name><name><surname>Konkel</surname> <given-names>JE</given-names></name><name><surname>Nakatsukasa</surname> <given-names>H</given-names></name><name><surname>Zanvit</surname> <given-names>P</given-names></name><name><surname>Goldberg</surname> <given-names>N</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Sun</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>ZJ</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>D-mannose induces regulatory T cells and suppresses immunopathology</article-title><source>Nature Medicine</source><volume>23</volume><fpage>1036</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1038/nm.4375</pub-id><pub-id pub-id-type="pmid">28759052</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>N</given-names></name><name><surname>Shabek</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ubiquitin ligases: structure, function, and regulation</article-title><source>Annual Review of Biochemistry</source><volume>86</volume><fpage>129</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060815-014922</pub-id><pub-id pub-id-type="pmid">28375744</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.62394.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Takeda</surname><given-names>Kiyoshi</given-names></name><role>Reviewing Editor</role><aff><institution>Osaka University</institution><country>Japan</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>In this study, the authors reveal downregulation of ACLY expression as a metabolic determinant of iTreg cell generation induced by TGFβ1. The authors show that neutral lipid content is decreased during iTreg compared to Th0 differentiation. Using complementary systems of overexpression, gene repression, and drug inhibition, the authors established that ACLY expression or activity is correlated with alterations in neutral lipid content in iTreg cells, and more importantly, changes in iTreg differentiation in both mouse and human cells. Mechanistically, the authors show that ACLY is targeted for ubiquitination and proteasomal degradation by CUL3-KLHL25 and further demonstrate that the CUL3-ACLY axis is important for regulating iTreg cell-dependent suppression of T cell proliferation and development of colitis and allergic diarrhea in vivo. This study will be of interest to those in the immunometabolism field and will have broader interest to those studying the therapeutic efficacy of ACLY inhibition in certain diseases.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;ACLY ubiquitination by CUL3-KLHL25 coordinates fatty acid synthesis to promote iTreg differentiation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Tadatsugu Taniguchi as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>In this study, the authors show that neutral lipid content is decreased during iTreg compared to Th0 differentiation. Using complementary systems of overexpression, gene repression, and drug inhibition, the authors established that ACLY expression or activity is correlated with alterations in neutral lipid content in iTreg cells, and more importantly, changes in iTreg differentiation in both mouse and human cells. Mechanistically, the authors show that ACLY is targeted for ubiquitination and proteasomal degradation by CUL3-KLHL25 and further demonstrate that the CUL3-ACLY axis is important for regulating iTreg cell-dependent suppression of T cell proliferation and development of colitis in vivo.</p><p>This is a well performed study that reveals downregulation of ACLY expression as a metabolic determinant of iTreg cell differentiation induced by TGFβ1.</p><p>Overall, the experiments were well performed and the study clearly shows the important roles of CUL3-KLHL25-mediated ACLY ubiquitination in iTreg differentiation. We have the following suggestions to improve the manuscript.</p><p>Essential revisions:</p><p>1. The authors provide convincing, but correlative, data for decreased neutral lipid staining (using BODIPY) in iTreg cells that is impacted by altered expression or activity of ACLY. BODIPY staining alone cannot distinguish if these changes are due only to alterations of de novo fatty acid synthesis. Indeed, such differences may also reflect changes in lipid uptake or even degradation via the fatty acid oxidation pathway. In addition, ACLY-derived acetyl-CoA can also serve as a precursor for the mevalonate-cholesterol biosynthesis pathway, as well as a substrate for acetyltransferase enzymes. Additional experiments are therefore required to demonstrate that downregulation of ACLY-dependent fatty acid synthesis is essential for iTreg cell differentiation, including:</p><p>a. Assess de novo lipid synthesis using radiolabeled acetate or glucose in ACLY-sufficient or -deficient iTreg (or SB204990-treated) cells to establish that the change in BODIPY staining is attributed to reduced lipid synthesis.</p><p>b. Add back palmitate, mevalonate, cholesterol, or acetate to iTreg cell cultures to establish a more direct relationship between ACLY downregulation/inhibition and fatty acid synthesis for iTreg cell generation.</p><p>c. Assess changes in histone acetylation by immunoblot, imaging, or flow cytometry analysis.</p><p>d. Measure nuclear levels of acetyl-CoA, as ACLY has been reported to enter the nucleus and influence histone acetylation (Sivanand et al., 2017 Mol Cell). The authors currently only assess changes in non-nuclear acetyl-CoA levels.</p><p>2. The authors suggest that downregulation of ACLY is important for promoting activation of CPT1a-dependent fatty acid oxidation, which has been implicated for iTreg cell generation in vitro. Do ACLY-deficient or SB204990-treated iTreg cells have increased rates of fatty acid oxidation?</p><p>3. TGFβ1 is also important for the development of thymic-derived Treg cells (Liu et al. 2008 Nat Immunol; Ouyang et al. 2010 Immunity). Is ACLY expression altered as cells differentiate from double-positive thymocytes to Treg precursors to mature Treg cells in the thymus?</p><p>4. For data presented in Figure 5, it remains unclear if the altered suppressive activity of CUL3- +/- ACLY-deficient iTreg cells in vitro or in vivo is due to differences in the proportion of iTreg cells or changes in suppressive function. To address this, the authors should perform the below experiments:</p><p>a. Assess the expression of surrogate molecules associated with Treg cell suppressive activity on Foxp3<sup>+</sup> iTreg cells under the various conditions (e.g. CTLA4, ICOS, TIGIT, IL-10, etc.).</p><p>b. Assess the number of Treg cells in the intestine of <italic>Cd4</italic>-cre:<italic>Cul3</italic>-deficient mice. Also, the authors should co-stain the intestinal Treg cells with RORγt and Helios to better distinguish peripherally-induced and thymic-derived Treg cells in the intestines (Sefik et al., 2015 Science; Ohnmacht et al., 2015 Science).</p><p>c. Use naïve T cells from Foxp3 reporter mice and sort purify Foxp3<sup>+</sup> iTreg cells for the in vitro suppressive assay.</p><p>d. Would be interesting if the authors investigate, for ex, allergic diarrhea, in which intestinal Treg cells are implicated in the prevention.</p><p>5. The therapeutic relevance of SB204990 in the DSS colitis model shown in Figure S8 should be discussed in the Results section of the manuscript, not only the Discussion.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.62394.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. The authors provide convincing, but correlative, data for decreased neutral lipid staining (using BODIPY) in iTreg cells that is impacted by altered expression or activity of ACLY. BODIPY staining alone cannot distinguish if these changes are due only to alterations of de novo fatty acid synthesis. Indeed, such differences may also reflect changes in lipid uptake or even degradation via the fatty acid oxidation pathway. In addition, ACLY-derived acetyl-CoA can also serve as a precursor for the mevalonate-cholesterol biosynthesis pathway, as well as a substrate for acetyltransferase enzymes. Additional experiments are therefore required to demonstrate that downregulation of ACLY-dependent fatty acid synthesis is essential for iTreg cell differentiation, including:</p></disp-quote><p>We totally agree with reviewers that comprehensive characterization of ACLY-repression-induced alterations in cell metabolism during iTreg cell differentiation is critical and pivotal. Thus we have performed a series of new experiments including radio-labelling and rescue assays as suggested to improve this manuscript.</p><disp-quote content-type="editor-comment"><p>a. Assess de novo lipid synthesis using radiolabeled acetate or glucose in ACLY-sufficient or -deficient iTreg (or SB204990-treated) cells to establish that the change in BODIPY staining is attributed to reduced lipid synthesis.</p></disp-quote><p>As the reviewer pointed out, BODIPY staining alone cannot pinpoint the contribution from ACLY-dependent alteration in FAS to de novo lipid synthesis. We thus have tracked [U-<sup>13</sup>C] glucose in iTreg cells inhibited for ACLY by SB204990 and found moderate to significant reductions in different <sup>13</sup>C-labelled fatty acids (new Figure 2A). This is consistent with decreased BODIPY staining in response to ACLY inhibition (previous Figure 1H) and again supports an important role for ACLY in de novo lipid synthesis. In addition, we have explained the isotope tracing analysis of FAS in the revised manuscript (please see page 6 line 135-138).</p><disp-quote content-type="editor-comment"><p>b. Add back palmitate, mevalonate, cholesterol, or acetate to iTreg cell cultures to establish a more direct relationship between ACLY downregulation/inhibition and fatty acid synthesis for iTreg cell generation.</p></disp-quote><p>Following the reviewer’s constructive suggestion, we have performed a series of rescue assays to carefully evaluate the functional consequences of ACLY-dependent metabolic alterations in iTreg differentiation. Upon the addition of mevalonate, cholesterol or acetate, upregulated iTreg differentiation induced by ACLY inhibition remained unchanged (new Figure 2—figure supplement 2A-C, Figure R1A-B). In line with this observation, levels of HMG-CoA, mevalonate, mevalonate-5-pyrophosphate, cholesterol as well as nuclear acetyl-CoA were unaffected in response to ACLY inhibition (new Figure 2—figure supplement 1A-D, Figure 2—figure supplement 3A-B). In addition, histone acetylation remained rather stable regardless of whether ACLY was inhibited or not (new Figure 2—figure supplement 3C-D). These results indicate that ACLY are unlikely to regulate iTreg differentiation via mevalonate-cholesterol biosynthesis pathway or histone acetylation.</p><p>Despite a reduction in FAS resulted from ACLY inhibition (new Figure 2A), addback of palmitate still could not rescue changes in iTreg differentiation induced by ACLY inhibition (new Figure 2—figure supplement 4A, Figure 2B). One may consider that the supplement of a single end-product is probably not sufficient enough to rescue the whole FAS. To evaluate the role of individual intermediate metabolite from FAS in ACLY-dependent regulation of iTreg differentiation, we separately blocked ACC and FASN in cells inhibited for ACLY by SB204990 (new Figure 2—figure supplement 4B). FASN inhibition by cerulenin, but not ACC inhibition by PF05175157, effectively abrogated ACLY-inhibition-induced iTreg differentiation (new Figure 2—figure supplement 4C), suggesting an important role for malonyl-CoA in ACLY-dependent regulation of iTreg differentiation. As the substrate of FASN, malonyl-CoA declined upon ACLY inhibition (new Figure 2—figure supplement 4D). Importantly, adding malonyl-CoA back totally blocked ACLY-inhibition-induced changes in iTreg differentiation (new Figure 2C). Together, these data argue that ACLY inhibition promotes iTreg differentiation probably by reducing malonyl-CoA. In the revised manuscript, these data have been selectively integrated and the main text has been modified accordingly (please see page 6-7 line 138-165).</p><disp-quote content-type="editor-comment"><p>c. Assess changes in histone acetylation by immunoblot, imaging, or flow cytometry analysis.</p></disp-quote><p>As suggested, we have assayed histone acetylation, which remained largely unchanged irrespective of the presence or absence of ACLY inhibitor (new Figure 2—figure supplement 3C-D). We also compared histone acetylation levels in Th0 and iTreg cells and found they were rather similar (Figure R2A-B). These results indicate that ACLY-dependent regulation of iTreg differentiation may not through histone acetylation. In the revised manuscript, this point has been integrated (please see page 7 line 147-149).</p><disp-quote content-type="editor-comment"><p>d. Measure nuclear levels of acetyl-CoA, as ACLY has been reported to enter the nucleus and influence histone acetylation (Sivanand et al., 2017 Mol Cell). The authors currently only assess changes in non-nuclear acetyl-CoA levels.</p></disp-quote><p>Following the reviewer’s suggestion, we have assessed nuclear acetyl-CoA levels at different conditions. Upon ACLY inhibition, the level of acetyl-CoA in nuclear fraction failed to change significantly (new Figure 2—figure supplement 3A-B). In a parallel assay comparing Th0 to iTreg cells, levels of nuclear acetyl-CoA also seemed rather similar (Figure R2C-D). In line with unchanged histone acetylation upon ACLY inhibition (new Figure 2—figure supplement 3C-D), these results suggest a dispensable role for ACLY in the regulation of nuclear acetyl-CoA level as well as histone acetylation during iTreg differentiation. In addition, we have also discussed the assessment of nuclear acetyl-CoA level in the revised manuscript (please see page 6-7 line 144-147).</p><disp-quote content-type="editor-comment"><p>2. The authors suggest that downregulation of ACLY is important for promoting activation of CPT1a-dependent fatty acid oxidation, which has been implicated for iTreg cell generation in vitro. Do ACLY-deficient or SB204990-treated iTreg cells have increased rates of fatty acid oxidation?</p></disp-quote><p>To address this point, we examined palmitate-dependent oxidation and CPT1 activity, which have been widely used for evaluating the rate of FAO (Hao et al., 2021; Kim et al., 2002). Upon ACLY inhibition, both palmitate-dependent oxidation and CPT1 activity were significantly elevated (new Figure 2D-E, R3A-B). In the revised manuscript, these data have been selectively integrated and the main text has been modified accordingly (please see page 7 line 169-170).</p><disp-quote content-type="editor-comment"><p>3. TGFβ1 is also important for the development of thymic-derived Treg cells (Liu et al. 2008 Nat Immunol; Ouyang et al. 2010 Immunity). Is ACLY expression altered as cells differentiate from double-positive thymocytes to Treg precursors to mature Treg cells in the thymus?</p></disp-quote><p>As suggested, we examined ACLY expression as cells differentiate from double-positive thymocytes to Treg precursors and mature Treg cells. During thymic-derived Treg cell development, ACLY expression increased gradually (Figure R5). Levels of ACLY in Treg precursors (CD4<sup>+</sup>CD8<sup>-</sup>CD25<sup>+</sup>Foxp3<sup>-</sup>) and mature Treg cells (CD4<sup>+</sup>CD8<sup>-</sup>CD25<sup>+</sup>Foxp3<sup>+</sup>) are significantly higher than that in double-positive thymocytes (CD4<sup>+</sup>CD8<sup>+</sup>) (Figure R5).</p><p>In contrast to iTreg cells that are dependent on FAO, tTreg cells have been found to rely on glycolysis and lipid synthesis (Priyadharshini et al., 2018; Zeng et al., 2013). Although both iTreg and tTreg differentiation are reliant on TGFβ1, different levels of ACLY may be of help for cells to establish distinct metabolic patterns. For instance, relatively high level of ACLY in tTreg cells (Figure R5) can support efficient lipid synthesis, which is known to be important for the suppressive function of tTreg cells (Zeng et al., 2013).</p><disp-quote content-type="editor-comment"><p>4. For data presented in Figure 5, it remains unclear if the altered suppressive activity of CUL3- +/- ACLY-deficient iTreg cells in vitro or in vivo is due to differences in the proportion of iTreg cells or changes in suppressive function. To address this, the authors should perform the below experiments:</p><p>a. Assess the expression of surrogate molecules associated with Treg cell suppressive activity on Foxp3<sup>+</sup> iTreg cells under the various conditions (e.g. CTLA4, ICOS, TIGIT, IL-10, etc.).</p></disp-quote><p>We truly appreciate the reviewer’s suggestion and have assessed the expression of surrogate molecules associated with the suppressive activity of iTreg cells under various conditions. Neither CUL3 deficiency (<italic>Cul3<sup>-/-</sup></italic>) nor the lack of CUL3 and ACLY (<italic>Cul3<sup>-/-</sup></italic> and si<italic>Acly</italic>) changed the expression of representative surrogate molecules, such as CTLA4, ICOS, TIGIT and IL-10, in Foxp3<sup>+</sup> iTreg cells (new Figure 4—figure supplement 4A). These data suggest that ACLY-dependent regulation of iTreg is probably not through modulation of its suppressive function. In the revised manuscript, we have integrated these new data and modified the main text accordingly (please see page 10 line 256-259).</p><disp-quote content-type="editor-comment"><p>b. Assess the number of Treg cells in the intestine of <italic>Cd4</italic>-cre:<italic>Cul3</italic>-deficient mice. Also, the authors should co-stain the intestinal Treg cells with RORγt and Helios to better distinguish peripherally-induced and thymic-derived Treg cells in the intestines (Sefik et al., 2015 Science; Ohnmacht et al., 2015 Science).</p></disp-quote><p>As the reviewer suggested, we have assessed the number of CD4<sup>+</sup>Foxp3<sup>+</sup> Treg cells in intestines from <italic>Cd4<sup>Cre</sup>Cul3<sup>fl/fl</sup></italic> mice and found a dramatic decrease as compared to WT mice (new Figure 4—figure supplement 3C, Figure R6). Furthermore, both peripherally-induced (Foxp3<sup>+</sup>RORγt<sup>+</sup>) and thymic-derived (Foxp3<sup>+</sup>Helios<sup>+</sup>) Treg cells were reduced (Figure R6). Together, these data confirmed the CUL3-deletion-induced impairment in iTreg differentiation in vivo. In the revised manuscript, these data have been selectively integrated and the main text has been modified accordingly (please see page 10 line 244-246).</p><disp-quote content-type="editor-comment"><p>c. Use naïve T cells from Foxp3 reporter mice and sort purify Foxp3<sup>+</sup> iTreg cells for the in vitro suppressive assay.</p></disp-quote><p>We took the advantage of the established <italic>Foxp3<sup>YFP-Cre</sup></italic> mice (Rubtsov et al., 2008) and isolated naïve CD4<sup>+</sup> T cells for functional assays. Following the transfection of siRNAs against <italic>Cul3</italic> and (or) <italic>Acly</italic>, naïve CD4<sup>+</sup> T cells were induced under iTreg differentiation condition prior to the analysis of Foxp3-YFP<sup>+</sup> iTreg cells. Clearly, <italic>Cul3</italic> knockdown by siRNA caused a reduction in Foxp3-YFP<sup>+</sup> iTreg cell number, which could be blocked by a simultaneous depletion of ACLY (new Figure 4—figure supplement 4B). These observations completely recapitulated our previous in vitro findings (new Figure 4E) and confirmed the important role of CUL3-ACLY axis during iTreg differentiation. In addition, the lack of CUL3 and (or) ACLY did not seem to affect the suppressive function of Foxp3-YFP<sup>+</sup> iTreg cells, because T cell proliferation remained unchanged, regardless of whether wild-type, si<italic>Cul3</italic>- or si<italic>Cul3</italic>/si<italic>Acly</italic>-treated Foxp3-YFP<sup>+</sup> iTreg cells were presented in the co-culture system (new Figure 4—figure supplement 4B). Meanwhile, the main text of the revised manuscript has been modified accordingly (please see page 10 line 259-264).</p><disp-quote content-type="editor-comment"><p>d. Would be interesting if the authors investigate, for ex, allergic diarrhea, in which intestinal Treg cells are implicated in the prevention.</p></disp-quote><p>Following the reviewer’s suggestion, we established an OVA-induced allergic diarrhea mouse model for the functional evaluation of CUL3-dependent ACLY degradation in iTreg differentiation (new Figure 6—figure supplement 4A). Upon OVA stimulation, mice developed diarrhea and exhibited upregulated OVA-specific IgE antibodies and mastocyte protease (MCPT-1) in the serum as expected (Kordowski et al., 2019) (new Figure 6—figure supplement 4B-E). Importantly, the adoptive transfer of wild-type (WT) iTreg cells, but not CUL3 deficient (<italic>Cul3<sup>-/-</sup></italic>) cells, into recipient mice remarkably alleviated diarrhea-associated defects (new Figure 6—figure supplement 4B-E). The alleviation effect from CUL3 deficiency on the diarrhea was rescued, when we used targeting siRNA to knock down <italic>Acly</italic> (new Figure 6—figure supplement 4B-E). Together, these in vivo data argue an important role for CUL3-mediated ACLY ubiquitination in the regulation of diarrhea. In the revised manuscript, we have explained the functional assessment for Treg cells derived from CUL3 and (or) ACLY deficiency in allergic diarrhea (please see page 12 line 311-320).</p><disp-quote content-type="editor-comment"><p>5. The therapeutic relevance of SB204990 in the DSS colitis model shown in Figure S8 should be discussed in the Results section of the manuscript, not only the Discussion.</p></disp-quote><p>Following the reviewer’s suggestion, we have discussed the therapeutic relevance of SB204990 in the DSS colitis model in the Results section of the manuscript (Page 12 line 304-307).</p><p>References</p><p>Essig K, Hu D, Guimaraes JC, Alterauge D, Edelmann S, Raj T, Kranich J, Behrens G, Heiseke A, Floess S, Klein J, Maiser A, Marschall S, Hrabĕ de Angelis M, Leonhardt H, Calkhoven CF, Noessner E, Brocker T, Huehn J, Krug AB, Zavolan M, Baumjohann D, Heissmeyer V. 2017. Roquin suppresses the PI3K-mTOR signaling pathway to inhibit T helper cell differentiation and conversion of Treg to Tfr cells. Immunity 47:1067-1082.e12. doi:10.1016/j.immuni.2017.11.008</p><p>Hao F, Tian M, Zhang X, Jin X, Jiang Y, Sun X, Wang Y, Peng P, Liu J, Xia C, Feng Y, Wei M. 2021. Butyrate enhances CPT1A activity to promote fatty acid oxidation and iTreg differentiation. Proc Natl Acad Sci 118:e2014681118. doi:10.1073/pnas.2014681118</p><p>Huang Q, Xu L, Ye L. 2019. T cell immune response within B-cell follicles. Advances in Immunology in China – Part A. pp. 155–171. doi:10.1016/bs.ai.2019.08.008</p><p>Kim J-Y, Koves TR, Yu G-S, Gulick T, Cortright RN, Dohm GL, Muoio DM. 2002. Evidence of a malonyl-CoA-insensitive carnitine palmitoyltransferase I activity in red skeletal muscle. Am J Physiol Metab 282:E1014–E1022. doi:10.1152/ajpendo.00233.2001</p><p>Kordowski A, Reinicke AT, Wu D, Orinska Z, Hagemann P, Huber-Lang M, Lee JB, Wang YH, Hogan SP, Köhl J. 2019. C5a receptor 1−/− mice are protected from the development of IgE-mediated experimental food allergy. Allergy Eur J Allergy Clin Immunol 74:767–779. doi:10.1111/all.13637</p><p>MacIver NJ, Michalek RD, Rathmell JC. 2013. Metabolic regulation of T lymphocytes. Annu Rev Immunol 31:259–283. doi:10.1146/annurev-immunol-032712-095956</p><p>Mathew R, Seiler MP, Scanlon ST, Mao A, Constantinides MG, Bertozzi-Villa C, Singer JD, Bendelac A. 2012. BTB-ZF factors recruit the E3 ligase cullin 3 to regulate lymphoid effector programs. Nature 491:618–621. doi:10.1038/nature11548</p><p>Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, Sullivan SA, Nichols AG, Rathmell JC. 2011. Cutting edge: Distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol 186:3299–3303. doi:10.4049/jimmunol.1003613</p><p>O’Connor RS, Guo L, Ghassemi S, Snyder NW, Worth AJ, Weng L, Kam Y, Philipson B, Trefely S, Nunez-Cruz S, Blair IA, June CH, Milone MC. 2018. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Sci Rep 8:1–9. doi:10.1038/s41598-018-24676-6</p><p>Patel CH, Powell JD. 2017. Targeting T cell metabolism to regulate T cell activation, differentiation and function in disease. Curr Opin Immunol 46:82–88. doi:10.1016/j.coi.2017.04.006</p><p>Priyadharshini B, Loschi M, Newton RH, Zhang J, Finn KK, Gerriets VA, Huynh A, Rathmell JC, Blazar BR, Turka LA. 2018. Cutting edge: TGF-β and phosphatidylinositol 3-kinase signals modulate distinct metabolism of regulatory T cell subsets. J Immunol 201:2215–2219. doi:10.4049/jimmunol.1800311</p><p>Raud B, Roy DG, Divakaruni AS, Tarasenko TN, Franke R, Ma EH, Samborska B, Hsieh WY, Wong AH, Stüve P, Arnold-Schrauf C, Guderian M, Lochner M, Rampertaap S, Romito K, Monsale J, Brönstrup M, Bensinger SJ, Murphy AN, McGuire PJ, Jones RG, Sparwasser T, Berod L. 2018. Etomoxir actions on regulatory and memory T cells are independent of Cpt1a-mediated fatty acid oxidation. Cell Metab 28:504-515.e7. doi:10.1016/j.cmet.2018.06.002</p><p>Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, Treuting P, Siewe L, Roers A, Henderson WR, Muller W, Rudensky AY. 2008. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28:546–558. doi:10.1016/j.immuni.2008.02.017</p><p>Saravia J, Zeng H, Dhungana Y, Bastardo Blanco D, Nguyen T-LM, Chapman NM, Wang Y, Kanneganti A, Liu S, Raynor JL, Vogel P, Neale G, Carmeliet P, Chi H. 2020. Homeostasis and transitional activation of regulatory T cells require c-Myc. Sci Adv 6:eaaw6443. doi:10.1126/sciadv.aaw6443</p><p>Zeng H, Yang K, Cloer C, Neale G, Vogel P, Chi H. 2013. mTORC1 couples immune signals and metabolic programming to establish Treg-cell function. Nature 499:485–490. doi:10.1038/nature12297</p><p>Zhang D, Chia C, Jiao X, Jin W, Kasagi S, Wu R, Konkel JE, Nakatsukasa H, Zanvit P, Goldberg N, Chen Q, Sun L, Chen Z, Chen W. 2017. D-mannose induces regulatory T cells and suppresses immunopathology. Nat Med 1–12. doi:10.1038/nm.4375</p></body></sub-article></article>